<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="review-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Exp. Biol. Med.</journal-id>
<journal-title>Experimental Biology and Medicine</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Exp. Biol. Med.</abbrev-journal-title>
<issn pub-type="epub">1535-3699</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">10537</article-id>
<article-id pub-id-type="doi">10.3389/ebm.2025.10537</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Experimental Biology and Medicine</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Critical role of alpha spectrin in DNA repair: the importance of &#x3bc;-calpain and Fanconi anemia proteins</article-title>
<alt-title alt-title-type="left-running-head">Lambert</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/ebm.2025.10537">10.3389/ebm.2025.10537</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Lambert</surname>
<given-names>Muriel W.</given-names>
</name>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1368886/overview"/>
</contrib>
</contrib-group>
<aff>
<institution>Department of Pathology, Immunology and Laboratory Medicine</institution>, <institution>Rutgers New Jersey Medical School</institution>, <addr-line>Newark</addr-line>, <addr-line>NJ</addr-line>, <country>United States</country>
</aff>
<author-notes>
<corresp id="c001">&#x2a;Correspondence: Muriel W. Lambert, <email>mlambert@njms.rutgers.edu</email>
</corresp>
<fn fn-type="other" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>ORCID: Muriel W. Lambert, <ext-link ext-link-type="uri" xlink:href="http://orcid.org/0000-0002-4503-0890">orcid.org/0000-0002-4503-0890</ext-link>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>01</day>
<month>05</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>250</volume>
<elocation-id>10537</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>02</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>04</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Lambert.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Lambert</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Nonerythroid spectrins are proteins important in maintaining the structural integrity and flexibility of the cell and nuclear membranes and are essential for a number of functionally important cellular processes. One of these proteins, nonerythroid &#x3b1; spectrin (&#x3b1;SpII), plays a critical role in DNA repair, specifically repair of DNA interstrand crosslinks (ICLs), where it acts as a scaffold, recruiting repair proteins to sites of damage. Loss or breakdown of &#x3b1;SpII is an important factor in a number of disorders. One of these is Fanconi anemia (FA), a genetic disorder characterized by bone marrow failure, chromosome instability, cancer predisposition, congenital abnormalities and a defect in DNA ICL repair. Significantly, breakdown of &#x3b1;SpII occurs in cells from a number of FA complementation groups, due to excessive cleavage by the protease, &#x3bc;-calpain, leading to defective repair of DNA ICLs in telomeric and non-telomeric DNA. Knockdown of &#x3bc;-calpain in FA cells by &#x3bc;-calpain siRNA results in restoration of &#x3b1;SpII levels to normal and repair of DNA ICLs in telomeric and non-telomeric DNA, demonstrating the importance of &#x3b1;SpII stability in the repair process. It is hypothesized that there is a mechanistic link between excessive cleavage of &#x3b1;SpII by &#x3bc;-calpain and defective DNA ICL repair in FA and that FA proteins, which are deficient in FA, play a key role in maintaining the stability of &#x3b1;SpII and preventing its cleavage by &#x3bc;-calpain. All of these events are proposed to be important key factors involved in the pathophysiology of FA and suggest new avenues for potential therapeutic intervention.</p>
</abstract>
<kwd-group>
<kwd>alpha spectrin</kwd>
<kwd>DNA repair</kwd>
<kwd>DNA interstrand crosslinks</kwd>
<kwd>&#x3bc;-calpain</kwd>
<kwd>Fanconi anemia proteins</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Impact statement</title>
<p>In the nucleus, the structural protein nonerythroid &#x3b1; spectrin (&#x3b1;SpII) plays a central role in repair of DNA interstrand crosslinks (ICLs). Significantly, there is a deficiency in &#x3b1;SpII in the genetic, bone marrow failure disorder, Fanconi anemia (FA), which is characterized by a defect in DNA ICL repair. This is due to excessive cleavage of &#x3b1;SpII by the protease, &#xb5;-calpain. Importantly, knockdown of &#xb5;-calpain, by siRNA, reverses cleavage of &#x3b1;SpII, restores its levels to normal and enables repair of DNA ICLs in FA cells. FA thus represents another disorder in which excessive cleavage of &#x3b1;SpII by &#xb5;-calpain correlates with a major characteristic, in this case defective DNA ICL repair. It demonstrates the importance of &#x3b1;SpII for the DNA ICL repair process. FA proteins are proposed to play a major role in regulating cleavage of &#x3b1;SpII by &#xb5;-calpain thus giving them another critical role in DNA repair.</p>
</sec>
<sec sec-type="intro" id="s2">
<title>Introduction</title>
<p>Cytoskeletal and nucleoskeletal proteins are critical for maintaining the structure, function and mechanical properties of eukaryotic cells [<xref ref-type="bibr" rid="B1">1</xref>&#x2013;<xref ref-type="bibr" rid="B11">11</xref>]. Of particular importance is spectrin, found in both erythroid and nonerythroid cells [<xref ref-type="bibr" rid="B12">12</xref>&#x2013;<xref ref-type="bibr" rid="B19">19</xref>]. Spectrin was first identified in erythrocytes and shown to be essential for cell membrane structure, integrity, and flexibility [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B20">20</xref>&#x2013;<xref ref-type="bibr" rid="B24">24</xref>]. Spectrin also plays a critical role in non-erythroid cells in both the cytoplasm and nucleus and is involved in maintaining the shape, flexibility and elasticity of both the cell and nuclear membranes and is essential for a number of functionally important cytoplasmic and nuclear processes, as well as for mechanical coupling between the nucleus and the cytoplasm [<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B13">13</xref>&#x2013;<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B25">25</xref>&#x2013;<xref ref-type="bibr" rid="B39">39</xref>]. Total loss of spectrin can lead to cell death [<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B40">40</xref>]. Nonerythroid spectrin has two subunits, &#x3b1;SpII and &#x3b2;SpII [<xref ref-type="bibr" rid="B14">14</xref>&#x2013;<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B35">35</xref>]. Of considerable interest, nuclear &#x3b1;SpII has been shown to directly interact with DNA and play a critical role in DNA repair and in the maintenance of the stability of chromosomes and telomeres after DNA damage [<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B41">41</xref>&#x2013;<xref ref-type="bibr" rid="B46">46</xref>]. It acts as a scaffold and aids in recruitment of repair proteins to sites of damage in both telomeric and non-telomeric DNA [<xref ref-type="bibr" rid="B42">42</xref>&#x2013;<xref ref-type="bibr" rid="B49">49</xref>].</p>
<p>Loss or breakdown of spectrin in cells leads to a deficiency in these processes and is clinically manifested in a number of disorders, one of which is the genetic disorder, Fanconi anemia (FA) [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B50">50</xref>]. FA is characterized by bone marrow failure, a marked propensity to develop cancer, multisystemic congenital abnormalities, chromosomal instability and a defect in ability to repair DNA interstrand cross-links (ICLs) [<xref ref-type="bibr" rid="B51">51</xref>&#x2013;<xref ref-type="bibr" rid="B69">69</xref>]. Lambert et. al. have shown a deficiency in &#x3b1;SpII in cells from FA patients from a number of FA complementation groups [<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B48">48</xref>]. This deficiency is due to the excessive activity of the protease, &#xb5;-calpain, which cleaves &#x3b1;SpII leading to its breakdown [<xref ref-type="bibr" rid="B69">69</xref>, <xref ref-type="bibr" rid="B70">70</xref>]. The breakdown of &#x3b1;SpII correlates with a defect in DNA ICL repair in FA cells in both nontelomeric and telomeric DNA and to chromosome instability [<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B69">69</xref>]. These studies have demonstrated that maintaining the stability of &#x3b1;SpII in the cell is critical for a number of important nuclear and cellular processes and for circumventing telomere dysfunction after DNA ICL damage [<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B69">69</xref>]. Lambert et al. have proposed that excessive cleavage of &#x3b1;SpII by &#x3bc;-calpain is an important factor in the pathogenesis of FA and a number of the clinical characteristics of this disorder [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B69">69</xref>].</p>
<p>This review will concentrate on the function of &#x3b1;SpII in the nucleus with emphasis on its interaction with non-telomeric and telomeric DNA, especially after DNA ICL damage, the importance of maintaining the stability of &#x3b1;SpII and preventing its breakdown by &#x3bc;-calpain, and the role of FA proteins in this process. The consequences of a loss or deficiency in &#x3b1;SpII on DNA repair, telomere integrity/function and chromosome stability after DNA damage, particularly in FA, will be discussed.</p>
</sec>
<sec id="s3">
<title>Overview of spectrin structure</title>
<p>&#x3b1;SpII is a long flexible protein which contains a modular structure composed of an extended array of triple &#x3b1;-helical repeats connected by short a-helical linker [<xref ref-type="bibr" rid="B14">14</xref>&#x2013;<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B71">71</xref>&#x2013;<xref ref-type="bibr" rid="B73">73</xref>]. This structure aids in its flexibility and ability to expand and contract [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B71">71</xref>&#x2013;<xref ref-type="bibr" rid="B73">73</xref>]. Nonerythroid spectrin has two subunits, &#x3b1;SpII and &#x3b2;SpII. There is one alpha spectrin gene and four beta spectrin genes [<xref ref-type="bibr" rid="B14">14</xref>&#x2013;<xref ref-type="bibr" rid="B17">17</xref>]. There are a number of different spectrin isoforms which originate by extensive mRNA splicing from these genes [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B27">27</xref>]. In all of these, &#x3b1;SpII and &#x3b2;SpII associate in an antiparallel fashion to form a heterodimer [<xref ref-type="bibr" rid="B14">14</xref>&#x2013;<xref ref-type="bibr" rid="B17">17</xref>]. &#x3b1;SpII consists of 21 triple helical repeats and &#x3b2;SpII contains 17 repeats [<xref ref-type="bibr" rid="B14">14</xref>&#x2013;<xref ref-type="bibr" rid="B17">17</xref>]. Two heterodimers can link head to head to form a tetramer [<xref ref-type="bibr" rid="B14">14</xref>&#x2013;<xref ref-type="bibr" rid="B17">17</xref>]. Nonerythroid spectrin (&#x3b1;SpII/&#x3b2;SpII) is comprised of numerous domains. &#x3b1;SpII contains an EF hand&#x2019;s domain on repeat 21, which is a site of Ca<sup>2&#x2b;</sup> binding and signaling (<xref ref-type="fig" rid="F1">Figure 1</xref>) [<xref ref-type="bibr" rid="B14">14</xref>&#x2013;<xref ref-type="bibr" rid="B17">17</xref>]. It contains a Src-homology 3 (SH3) domain in repeat 10, which plays an important role in proteinprotein interactions and is involved in signal transduction and intracellular signaling (<xref ref-type="fig" rid="F1">Figure 1</xref>) [<xref ref-type="bibr" rid="B14">14</xref>&#x2013;<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B74">74</xref>, <xref ref-type="bibr" rid="B78">78</xref>&#x2013;<xref ref-type="bibr" rid="B81">81</xref>]. The SH3 domain has a binding site for a kinase, c-Src, lowmolecular weight phosphotyrosine phosphatase (LMW-PTP) and FANCG, a Fanconi anemia (FA) protein. &#x3b1;SpII has a site of cleavage by the protease, calpain, in repeat 11 between residues Y<sub>1176</sub> and G<sub>1177.</sub> [<xref ref-type="bibr" rid="B75">75</xref>, <xref ref-type="bibr" rid="B76">76</xref>] There is a caspase cleavage site at residue Asp1185, which is activated during apoptosis [<xref ref-type="bibr" rid="B82">82</xref>]. &#x3b1;SpII also has a calmodulin binding domain in repeat 11, which can modulate spectrin cleavage by &#xb5;-calpain and caspase [<xref ref-type="bibr" rid="B83">83</xref>, <xref ref-type="bibr" rid="B84">84</xref>]. Proteolytic cleavage of &#x3b1;SpII by &#xb5;-calpain leads to its decreased stability and loss of function, which makes regulation of &#xb5;-calpain cleavage of &#x3b1;SpII critical for maintaining normal cell and nuclear functioning [<xref ref-type="bibr" rid="B74">74</xref>, <xref ref-type="bibr" rid="B76">76</xref>, <xref ref-type="bibr" rid="B78">78</xref>]. There is also a ubiquitination site in repeat 21 and a suggested E2/E3-ubiquitin-conjugating/ligating site in repeat 20 [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B26">26</xref>]. &#x3b2;SpII has an actin-binding domain on repeat 1, and a pleckstrin homology domain on repeat 7, which is involved in cell signaling, organization of the cytoskeleton, and aiding in the localization of &#x3b2;SpII to the plasma membrane [<xref ref-type="bibr" rid="B14">14</xref>&#x2013;<xref ref-type="bibr" rid="B17">17</xref>]. &#x3b1;SpII and &#x3b2;SpII assemble laterally to form heterodimers that assemble into tetramers [<xref ref-type="bibr" rid="B14">14</xref>&#x2013;<xref ref-type="bibr" rid="B17">17</xref>]. The tertiary structure of the spectrin repeat imparts elasticity to the protein [<xref ref-type="bibr" rid="B14">14</xref>&#x2013;<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B71">71</xref>&#x2013;<xref ref-type="bibr" rid="B73">73</xref>]. The structural characteristics of &#x3b1;SpII/&#x3b2;SpII enable it to interact with a number of different cellular proteins and participate in a number of important physiological pathways in the cell in both the nucleus and the cytoplasm. Numerous reviews are available with a moredetailed description of spectrin structure [<xref ref-type="bibr" rid="B14">14</xref>&#x2013;<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B24">24</xref>&#x2013;<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B71">71</xref>&#x2013;<xref ref-type="bibr" rid="B73">73</xref>].</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>The structure and domains of human non-erythroid alpha spectrin (&#x3b1;SpII). &#x3b1;SpII is composed of 21 triple helical repeats. Repeat 10 contains a Src-homology 3 (SH3) domain which is a site of protein-protein interactions. Three proteins targeting this site are: c-src, a kinase; low molecular weight phosphotyrosine phosphatase (PTP); and FANCG. Repeat 11 has a site of cleavage by the protease, &#x3bc;-calpain, and also contains a binding domain for calmodulin. There is a suggested E2/E3 ubiquitin protein conjugating/ligating site (E2/E3) in repeat 20 and a ubiquitination site (Ub) in repeat 21. At the C-terminus of &#x3b1;SpII are two ER-hand domains which bind calcium. Domains 20 and 21 mediate the dimerization of &#x3b1;SpII at its C-terminus with the N-terminus of &#x3b2;SpII. This structure of &#x3b1;SpII is based on studies and models of a number of investigators. [<xref ref-type="bibr" rid="B14">14</xref>&#x2013;<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B74">74</xref>&#x2013;<xref ref-type="bibr" rid="B77">77</xref>].</p>
</caption>
<graphic xlink:href="ebm-250-10537-g001.tif"/>
</fig>
</sec>
<sec id="s4">
<title>Spectrin and its role in the cytoplasm</title>
<p>Spectrin is a multifunctional protein, as is evidenced by the numerous proteins which interact with both &#x3b1;SpII and &#x3b2;SpII. Goodman and colleagues have created the Spectrinome using Human Proteome, Human Reactome and Human Atlas data which clearly demonstrates the multitude of cellular pathways and functions in which spectrin is involved in the cytoplasm, the nucleus and the cell surface [<xref ref-type="bibr" rid="B14">14</xref>]. Since spectrin&#x2019;s numerous interacting protein partners demonstrate the multitude of roles spectrin plays in the cell, it is important to more fully understand these interactions and their impact on cellular function.</p>
<p>One of the best known and critical roles of &#x3b1;SpII/&#x3b2;SpII is providing structural integrity for cell membranes [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B85">85</xref>, <xref ref-type="bibr" rid="B86">86</xref>]. It acts as a scaffold interacting with ankyrin, actin and other cytoskeletal proteins to form a network crucial for maintaining mechanical support, shape, flexibility and elasticity to the cell membrane [<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B85">85</xref>&#x2013;<xref ref-type="bibr" rid="B89">89</xref>]. &#x3b1;SpII is involved in cell movement and adhesion via interactions with proteins involved in actin dynamics (<xref ref-type="fig" rid="F2">Figure 2</xref>) [<xref ref-type="bibr" rid="B31">31</xref>&#x2013;<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B89">89</xref>]. &#x3b1;SpII plays a role in actin filament reorganization which is critical for a number of processes such as lamellipodia extension and immunological synapse formation between T-cells and antigen-presenting cells [<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B89">89</xref>]. The SH3 domain of &#x3b1;SpII has been shown to bind to proteins involved in actin polymerization and reorganization and plays a crucial role in this process during cell-cell contact, cell adhesion, cell spreading and migration [<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B89">89</xref>&#x2013;<xref ref-type="bibr" rid="B91">91</xref>]. Spectrin interacts with proteins involved in intracellular traffic. It is involved in vesicle and organelle mediated transport [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B92">92</xref>]. In neurons, &#x3b1;SpII/&#x3b2;SpII and &#x3b1;SpII/&#x3b2;SpIII have an essential role in synaptic vesicle trafficking and synaptic transmission [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B93">93</xref>]. &#x3b2;SpIII associates with the microtubule motor proteins, kinesin and dynein, and is involved in anterograde and retrograde transport of cargo in axons [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B94">94</xref>&#x2013;<xref ref-type="bibr" rid="B96">96</xref>]. &#x3b1;SpII and &#x3b2;SpII associate with synaptic vesicles via synapsin I and are critical for this process [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B97">97</xref>]. &#x3b1;SpII and &#x3b2;SpII have been identified associated with melanosomes in human melanocytes and are thought to be involved in melanosome transport in these cells [<xref ref-type="bibr" rid="B98">98</xref>]. Goodman et al have also shown that erythroid spectrin has E2/E3 chimeric ubiquitin conjugating and ligating activity and is capable of ubiquitinating not only alpha spectrin but also ankyrin, band 3, and protein 4.1 [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B99">99</xref>, <xref ref-type="bibr" rid="B100">100</xref>]. Goodman et al. have proposed that &#x3b1;SpII has similar E2/E3 ubiquitinating activity in the cytoplasm and the nucleus in non-erythroid cells [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B99">99</xref>, <xref ref-type="bibr" rid="B100">100</xref>]. This activity is very important for protein-protein interactions and the role they play in normal physiological processes in the cell. Thus, &#x3b1;SpII along with &#x3b2;SpII are components of a spectrin scaffold which is critical for a large number of physiological processes in the cytoplasm.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Roles for &#x3b1;SpII in the nucleus and cytoplasm. &#x3b1;SpII is involved in multiple functions in both the nucleus and cytoplasm of human non-erythroid cells and thus has an important impact on a number of different cellular pathways.</p>
</caption>
<graphic xlink:href="ebm-250-10537-g002.tif"/>
</fig>
</sec>
<sec id="s5">
<title>Spectrin and its structural role in the nucleus</title>
<p>Just as interactions of spectrin with specific proteins in the cytoplasm are critical for cellular function, its interactions with both proteins and DNA in the nucleus is critical for nuclear function. Within the nucleus, nonerythroid spectrin is a component of a nucleoskeletal network which plays an essential role in maintaining the structural integrity and elasticity of the nucleus as well as in repair of damage to both nontelomeric and telomeric DNA (<xref ref-type="fig" rid="F2">Figure 2</xref>) [<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B15">15</xref>&#x2013;<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B101">101</xref>]. Both &#x3b1;SpII and two isoforms of &#x3b2;-spectrin (&#x3b2;SpII and &#x3b2;SpIV&#x2211;5) have been identified in the nucleus [<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B39">39</xref>]. Studies have shown that &#x3b1;SpII is present in the peripheral nucleoskeleton, where it interacts with lamins A and B, actin, and nuclear myosin and is anchored to the nuclear envelope by emerin and protein 4.1 [<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B102">102</xref>]. It makes an important contribution to the biomechanical properties of these nucleoskeleton proteins and to nuclear envelope support [<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B102">102</xref>]. It forms a complex with lamins A and B, actin, nuclear myosin, and the LINC complex protein, SUN2, and plays an important role in coupling the nucleoskeleton to the cytoskeleton [<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B41">41</xref>]. &#x3b1;SpII is also associated with the inner nucleoskeleton where it interacts with DNA repair proteins, chromatin remodeling proteins and proteins involved in transcription and RNA processing [<xref ref-type="bibr" rid="B6">6</xref>&#x2013;<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B42">42</xref>].</p>
<p>The cortical network &#x3b1;SpII forms with lamin and actin at the nuclear envelop plays a role in maintaining the elasticity and structural integrity of the nucleus (<xref ref-type="fig" rid="F2">Figure 2</xref>) [<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B37">37</xref>]. Knock-down of &#x3b1;SpII in HeLa cells to levels that are approximately 50% of those found in control cells leads to a decrease in ability of the nucleus to recover from compression [<xref ref-type="bibr" rid="B37">37</xref>]. This has been attributed to loss of membrane elasticity due to decreased &#x3b1;SpII [<xref ref-type="bibr" rid="B37">37</xref>]. &#x3b1;SpII&#x2019;s modular structure of triple alpha-helical repeats makes an important contribution to the structural stability, elasticity and mechanical resilience of the nucleus and to its ability to recover from compression [<xref ref-type="bibr" rid="B37">37</xref>].</p>
<p>Thus, &#x3b1;SpII is an important scaffolding protein which represents 2&#x2013;3% of the total protein in eukaryotic cells [<xref ref-type="bibr" rid="B14">14</xref>]. It has a myriad of functions and any defects or deficiencies in this protein would be central to pathological changes occurring in the cell structure and function (<xref ref-type="fig" rid="F2">Figure 2</xref>). Therefore, maintaining &#x3b1;SpII stability is critical for normal cell functioning. Excessive cleavage of &#x3b1;SpII can upset normal cellular homeostasis and result in various human disease states and disorders. These points will be discussed below.</p>
</sec>
<sec id="s6">
<title>&#x3b1;II spectrin plays a critical role in DNA repair in the nucleus</title>
<p>In addition to its structural role in the nucleus, &#x3b1;SpII has been shown to have an essential function in the nucleus in repair of DNA damage. Lambert and colleagues have demonstrated that in human cells &#x3b1;SpII plays a critical role in repair of DNA interstrand cross-links (ICLs) in both non-telomeric and telomeric DNA and is needed for chromosomal stability after DNA damage [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B42">42</xref>&#x2013;<xref ref-type="bibr" rid="B49">49</xref>, <xref ref-type="bibr" rid="B69">69</xref>]. There are numerous lines of evidence which demonstrate the important role of &#x3b1;SpII in DNA repair: (1) &#x3b1;SpII binds directly to DNA at sites of ICLs; (2) &#x3b1;SpII recruits repair proteins to these sites; (3) &#x3b1;SpII is needed for production of incisions produced by the endonuclease XPF-ERCC1 at sites of ICLs; and (4) &#x3b1;SpII is critical for repair of telomeric DNA and telomere integrity after DNA ICL damage [<xref ref-type="bibr" rid="B42">42</xref>&#x2013;<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B69">69</xref>]. Thus, &#x3b1;SpII is important in DNA repair processes in the nucleus and maintenance of telomere integrity after DNA damage. These points will be discussed below.</p>
<sec id="s6-1">
<title>&#x3b1;SpII localizes to sites of DNA ICLs and binds directly to DNA at these sites</title>
<p>Lambert <italic>et al.</italic> have demonstrated that &#x3b1;SpII from HeLa cell nuclei, as well as purified bovine brain &#x3b1;SpII, bind directly to a DNA substrate containing a 4,5&#x2032;8-trimethylpsoralen (TMP) plus UVA light induced ICL [<xref ref-type="bibr" rid="B42">42</xref>]. Based on the crystal structure of &#x3b1;SpIl, it has been proposed that it binds to the minor groove of DNA which opens up after ICL formation [<xref ref-type="bibr" rid="B42">42</xref>]. &#x3b1;SpII&#x2019;s binding to the damaged DNA is specific for the ICL; it does not bind to DNA containing a TMP monoadduct [<xref ref-type="bibr" rid="B42">42</xref>]. In HeLa and human lymphoblastoid cells damaged with a DNA ICL agent, 8-methoxysporalen (8-MOP) plus UVA light or mitomycin C (MMC), &#x3b1;SpII localizes in damage induced nuclear foci which are sites of DNA ICLs [<xref ref-type="bibr" rid="B42">42</xref>&#x2013;<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B49">49</xref>, <xref ref-type="bibr" rid="B69">69</xref>]. These studies provide strong evidence that &#x3b1;SpII plays a role in the damage recognition steps of the DNA ICL repair process.</p>
</sec>
<sec id="s6-2">
<title>&#x3b1;SpII is needed for recruitment of XPF-ERCC1 and repair proteins to sites of ICLs and production of incisions at these sites</title>
<p>&#x3b1;SpII colocalizes in damaged-induced nuclear foci with proteins involved in DNA ICL repair. These include FANCA, FANCF, FANCG, and XPF-ERCC1 [<xref ref-type="bibr" rid="B42">42</xref>&#x2013;<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B69">69</xref>]. XPF-ERCC1 is involved in the unhooking of the ICL and production of endonucleolytic incisions at the site of the ICL [<xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B103">103</xref>&#x2013;<xref ref-type="bibr" rid="B106">106</xref>]. Lambert and colleagues demonstrated that, after normal human lymphoblastoid cells or HeLa cells are damaged with a DNA ICL agent, &#x3b1;SpII colocalizes with XPF at damage-induced nuclear foci [<xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B69">69</xref>]. Time course studies have shown that &#x3b1;SpII co-localizes with XPF at the same nuclear foci, with foci first appearing 10&#xa0;h after ICL damage with 8-MOP plus UVA light or MMC (<xref ref-type="fig" rid="F3">Figure 3</xref>) [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B43">43</xref>]. Foci peak at 16h and disappear by 24h when ICLs are no longer present [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B43">43</xref>]. The same time course and co-localization observed with &#x3b1;SpII and XPF was also observed with the repair proteins FANCA and FANCF [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B43">43</xref>]. This indicates that both &#x3b1;SpII and XPF are involved in the same events in DNA ICL repair and suggests that FANCA and FANCF may also play a role.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Time course for appearance of &#x3b1;SpII, XPF, FANCD2, and <inline-formula id="inf1">
<mml:math id="m1">
<mml:mrow>
<mml:mi mathvariant="normal">&#x3b3;</mml:mi>
</mml:mrow>
</mml:math>
</inline-formula>-H2AX nuclear foci after damage of normal human cells with a DNA ICL agent. The percentage of nuclei showing multiple &#x3b1;SpII, XPF, FANCD2, and <inline-formula id="inf2">
<mml:math id="m2">
<mml:mrow>
<mml:mi mathvariant="normal">&#x3b3;</mml:mi>
</mml:mrow>
</mml:math>
</inline-formula>-H2AX foci was determined at time points from 0 to 72&#xa0;h after treatment with 8-MOP plus UVA light. Nuclei containing four or more foci were counted as positive. &#x3b1;SpII foci co-localized with XPF foci and had a similar time course after damage of cells with 8-MOP plus UVA light. These foci appeared after FANCD2 foci and had a different time course than the FANCD2 foci. Error bars represent SEM. (Reproduced from Zhang et al., [<xref ref-type="bibr" rid="B49">49</xref>] with permission from John Wiley and Sons).</p>
</caption>
<graphic xlink:href="ebm-250-10537-g003.tif"/>
</fig>
<p>Additional evidence that &#x3b1;SpII is critical for recruitment of XPF and these repair proteins to sites of ICLs has been demonstrated by immunofluorescence studies in which &#x3b1;SpII has been knocked down by siRNA [<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B46">46</xref>]. Since &#x3b1;SpII is an essential protein for cell survival, total loss of this protein results in cell death [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B107">107</xref>, <xref ref-type="bibr" rid="B108">108</xref>]. Cells survive, however, when levels are reduced to 35&#x2013;40% of normal [<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B46">46</xref>]. Reduction of &#x3b1;SpII to these levels followed by damaging DNA with an ICL agent has been shown to result in decreased formation of damage-specific &#x3b1;SpII foci in these cells and loss of localization of XPF to the sites of damage [<xref ref-type="bibr" rid="B45">45</xref>]. FA proteins are present in these cells and FANCA and FANCF also localize to the sites of damage with XPF [<xref ref-type="bibr" rid="B45">45</xref>]. Thus, &#x3b1;SpII is needed for the recruitment and localization of XPF as well as FANCA and FANCF to sites of DNA ICLs indicating their involvement in ICL repair. Corroborating these findings are studies which have shown that inhibition of expression of the &#x3b1;SpII gene, <italic>SPTAN1</italic>, by miR-125-3p, leads to disruption of localization of XPF and FANCA to mitomycin C induced foci after treatment of lung cancer cells with this DNA interstrand cross-linking agent [<xref ref-type="bibr" rid="B109">109</xref>]. This has been suggested as a novel pathway for interrupting repair of DNA ICLs and enhancing the anticancer function of DNA ICL agents [<xref ref-type="bibr" rid="B109">109</xref>].</p>
<p>Further support for the importance of &#x3b1;SpII for incisions produced by XPF-ERCC1 is provided by studies which have demonstrated that, on a DNA substrate containing a site-specific tri-methylpsoralen (TMP) ICL, XPF-ERCC1 produces incisions at the site of a DNA ICL [<xref ref-type="bibr" rid="B42">42</xref>]. Purified bovine &#x3b1;SpII enhances these incisions but does not itself produce incisions at the site of the ICL [<xref ref-type="bibr" rid="B42">42</xref>]. A purified monoclonal antibody against &#x3b1;SpII from normal human lymphoblastoid cells inhibited these incisions [<xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B48">48</xref>]. Thus the presence of &#x3b1;SpII is critical for the incisions produced by XPF-ERCC1 at sites of ICLs. The studies described above have led Lambert and colleagues to develop a model in which &#x3b1;SpII acts as a scaffold to aid in recruitment of repair proteins such as XPF-ERCC1 to sites of DNA ICLs; loss of &#x3b1;SpII results in a deficiency in recruitment of XPF and decreased incisions at sites of ICLs leading to a deficiency in DNA repair [<xref ref-type="bibr" rid="B42">42</xref>].</p>
</sec>
<sec id="s6-3">
<title>The SH3 domain of &#x3b1;SpII is an important site of recruitment for XPF-ERCC1 and repair proteins to sites of DNA ICLs</title>
<p>An important question is by what mechanism does &#x3b1;SpII recruit repair proteins to sites of ICLs? As mentioned above, &#x3b1;SpII consists of 21 triple-helical repeats [<xref ref-type="bibr" rid="B14">14</xref>&#x2013;<xref ref-type="bibr" rid="B17">17</xref>]. There is a Src-homology 3 (SH3) domain in the 10th repeat (<xref ref-type="fig" rid="F1">Figure 1</xref>) [<xref ref-type="bibr" rid="B14">14</xref>&#x2013;<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B78">78</xref>]. SH3 domains are modular domains which are important in protein-protein interactions and protein network assembly [<xref ref-type="bibr" rid="B79">79</xref>, <xref ref-type="bibr" rid="B110">110</xref>]. There are three major classes of protein ligands which bind to SH3 domains, class I, class II and class I@ [<xref ref-type="bibr" rid="B74">74</xref>, <xref ref-type="bibr" rid="B79">79</xref>&#x2013;<xref ref-type="bibr" rid="B81">81</xref>]. The SH3 domain of &#x3b1;SpII has a consensus sequence which preferentially binds to class 1@ ligands [<xref ref-type="bibr" rid="B74">74</xref>]. A number of FA proteins have consensus sequences that bind to SH3 domains and have the potential to bind to cellular proteins containing these domains [<xref ref-type="bibr" rid="B101">101</xref>]. Of particular interest, FANCG has a class1@ consensus sequence [<xref ref-type="bibr" rid="B101">101</xref>]. Lambert et al have carried out studies using sitedirected mutagenesis and yeast two hybrid analysis and have shown that FANCG binds directly to the SH3 domain of &#x3b1;SpII via this consensus sequence [<xref ref-type="bibr" rid="B101">101</xref>]. FANCG also binds directly to XPF-ERCC1 [<xref ref-type="bibr" rid="B101">101</xref>]. FANCG contains seven tetratricopeptide repeat (TPR) motifs, which are motifs that are involved in protein-protein interactions [<xref ref-type="bibr" rid="B111">111</xref>&#x2013;<xref ref-type="bibr" rid="B114">114</xref>]. TPR motifs 1, 2, 3, and 6 in FANCG bind directly to the central domain of ERCC1 (residues 120&#x2013;220) [<xref ref-type="bibr" rid="B115">115</xref>]. ERCC1 binds to XPF by its C-terminal domain (residues 220&#x2013;297) [<xref ref-type="bibr" rid="B116">116</xref>&#x2013;<xref ref-type="bibr" rid="B118">118</xref>]. XPF in turn binds to ERCC1 through its C-terminal domain, which differs from its nuclease domain, and produces incisions at the sites of DNA ICLs [<xref ref-type="bibr" rid="B118">118</xref>, <xref ref-type="bibr" rid="B119">119</xref>]. Thus the SH3 domain of &#x3b1;SpII plays an important role in the ability of &#x3b1;SpII to recruit XPF-ERCC1, via FANCG, to sites of ICLs, enabling it to create incisions at the site of damage. Knocking down &#x3b1;SpII eliminates its binding to sites of DNA ICLs and recruitment of XPF-ERCC1 to these sites [<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B46">46</xref>]. This, in turn, results in reduction in production of incisions on damaged DNA [<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B46">46</xref>]. Whether &#x3b1;SpII is involved in additional steps in the repair process has not yet been determined.</p>
</sec>
<sec id="s6-4">
<title>A model for the role of &#x3b1;SpII in the DNA ICL repair pathway</title>
<p>Repair of DNA ICLs can occur in both replicating and non-replicating DNA [<xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B120">120</xref>&#x2013;<xref ref-type="bibr" rid="B125">125</xref>]. This repair process is particularly important in S phase of the cell cycle when DNA replication is stalled at the site of an ICL. Stalled DNA replication forks can trigger DNA ICL repair, thus making replication-coupled ICL repair extremely critical for cell survival [<xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B120">120</xref>&#x2013;<xref ref-type="bibr" rid="B125">125</xref>]. Several models have been proposed for repair of ICLs at stalled replication forks. Three of the major pathways for replication-coupled ICL repair are: (1) The Fanconi anemia pathway, which is triggered when two replication forks converge on an ICL. This pathway involves a large number of proteins and a complex series of steps resulting in production of incisions in DNA and unhooking of the ICL; (2) The Neil3 pathway, in which ICLs are resolved by a DNA glycosylase and cleavage of one of the two N-glycosyl bonds forming the ICL; and (3) The acetaldehyde pathway, which denotes a mechanism for repair of acetaldehyde-induced ICLs [<xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B125">125</xref>]. In some instances unhooking involves incision of the ICL via the FA pathway and in others the ICL may undergo enzymatic reversal [<xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B125">125</xref>].</p>
<p>Replication-coupled ICL repair has been extensively studied in cells from patients with Fanconi anemia (FA) who are deficient in ability to repair DNA interstrand crosslinks [<xref ref-type="bibr" rid="B57">57</xref>&#x2013;<xref ref-type="bibr" rid="B61">61</xref>, <xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B123">123</xref>, <xref ref-type="bibr" rid="B124">124</xref>]. FA is a genetic disorder, which, in addition to defective DNA ICL repair, is characterized by bone marrow failure, congenital abnormalities, chromosome instability and a predisposition to develop a variety of cancers [<xref ref-type="bibr" rid="B51">51</xref>, <xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B61">61</xref>&#x2013;<xref ref-type="bibr" rid="B68">68</xref>]. There are 22 different FA genes (<italic>FANCA</italic> to <italic>FANCW</italic>). Germline mutations in any one of these genes can cause the disorder. The FANC proteins expressed by these genes are all involved in replication-coupled DNA repair and the pathway in which they are involved is known as the Fanconi anemia (FA) pathway [<xref ref-type="bibr" rid="B57">57</xref>&#x2013;<xref ref-type="bibr" rid="B61">61</xref>, <xref ref-type="bibr" rid="B104">104</xref>, <xref ref-type="bibr" rid="B126">126</xref>&#x2013;<xref ref-type="bibr" rid="B131">131</xref>]. Since &#x3b1;SpII has been shown to play a critical role in ICL repair during S phase of the cell cycle, to directly interact with proteins in the FA pathway, and to be important in the initial damage recognition and incision steps of the ICL repair process, the involvement of &#x3b1;SpII in this pathway will be described [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B42">42</xref>&#x2013;<xref ref-type="bibr" rid="B46">46</xref>].</p>
<p>The initial damage recognition step of the ICL repair process is critical. In replication-coupled DNA ICL repair, the site of damage is located at a stalled replication fork [<xref ref-type="bibr" rid="B57">57</xref>&#x2013;<xref ref-type="bibr" rid="B59">59</xref>, <xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B121">121</xref>]. Lambert and colleagues have proposed a model for the mechanism of action of &#x3b1;SpII in ICL repair in the FA repair pathway (<xref ref-type="fig" rid="F4">Figure 4</xref>) [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B50">50</xref>]. It is based on studies on the interaction of &#x3b1;SpII with DNA containing ICLs and with proteins involved in the ICL repair process and on previous models for ICL repair [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B121">121</xref>, <xref ref-type="bibr" rid="B124">124</xref>, <xref ref-type="bibr" rid="B136">136</xref>]. Although &#x3b1;SpII is not a FANC protein, it plays a critical role in this pathway [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B50">50</xref>]. In this pathway, replication forks converge at the site of an ICL and the CDC45/MCM2-7/GINS (CMG) helicase complex on the leading strand is unloaded [<xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B126">126</xref>, <xref ref-type="bibr" rid="B130">130</xref>]. FANCM and a group of interacting proteins recognize the stalled replication fork and localize to the DNA [<xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B125">125</xref>, <xref ref-type="bibr" rid="B127">127</xref>, <xref ref-type="bibr" rid="B131">131</xref>]. The FANCM complex helps recruit the FA core complex (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FAAP20 and FAAP100), which has E3 ubiquitin ligase activity [<xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B125">125</xref>, <xref ref-type="bibr" rid="B131">131</xref>]. FANCD2/FANCI localize at the replication fork stalled at the site of the ICL [<xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B136">136</xref>&#x2013;<xref ref-type="bibr" rid="B139">139</xref>]. The core complex recruits a ubiquitinconjugating enzyme, UBE2T (FANCT), which monoubiquitinates FANCI and FANCD2 (the ID complex) (<xref ref-type="fig" rid="F4">Figure 4</xref>). [<xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B125">125</xref>, <xref ref-type="bibr" rid="B136">136</xref>&#x2013;<xref ref-type="bibr" rid="B139">139</xref>] &#x3b1;SpII subsequently binds to the site of an ICL on DNA downstream of FANCD2 [<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B50">50</xref>].</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>A model for the role of &#x3b1;IISp in replication-coupled DNA ICL repair. When DNA replication is stalled at the site of an ICL and replication forks converge, the CMG helicase complex on the leading strand stalls and is unloaded. FANCM recognizes the stalled replication fork and localizes to the damaged DNA. The FANCM complex recruits the FA core complex. FANCD2 and FANCI localize to the site of damage at the stalled replication fork. The core complex recruits UBE2T (FANCT), which monoubiquitinates FANCD2 and FANCI. &#x3b1;SpII subsequently binds to DNA at the site of the ICL downstream of FANCD2-Ub and acts as a scaffold aiding in the recruitment of repair proteins to the site of damage. FANCG binds to the SH3 domain of &#x3b1;SpII and XPF-ERCC1 is recruited and binds to FANCG-&#x3b1;SpII. XPF then produces incisions at the site of damage and is involved in the unhooking of the ICL. SLX4/FANCP plays a role in this step. Translesion DNA synthesis then occurs by a translesion polymerase leading to bypassing the ICL. This is followed by additional steps which include homologous recombination (HR) and adduct removal by nucleotide excision repair (NER). This model emphasizes the role of &#x3b1;SpII in the initial damage-recognition and incision steps of the DNA ICL repair process. It is based on studies on the interaction of &#x3b1;SpII with DNA containing ICLs, on the involvement of numerous proteins involved in the repair process and on other models for ICL repair [<xref ref-type="bibr" rid="B42">42</xref>&#x2013;<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B104">104</xref>, <xref ref-type="bibr" rid="B109">109</xref>, <xref ref-type="bibr" rid="B127">127</xref>, <xref ref-type="bibr" rid="B132">132</xref>&#x2013;<xref ref-type="bibr" rid="B135">135</xref>]. (Modified from Lambert [<xref ref-type="bibr" rid="B50">50</xref>], with permission of Sage Publications Ltd.).</p>
</caption>
<graphic xlink:href="ebm-250-10537-g004.tif"/>
</fig>
<p>After &#x3b1;SpII binds to the DNA, it aids in the recruitment of XPF-ERCC1 to the site of the ICL via recruitment of FANCG [<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B50">50</xref>]. As described above, FANCG directly binds to the SH3 domain of &#x3b1;SpII via its class 1@ consequence sequence and recruits XPFERCC1 [<xref ref-type="bibr" rid="B101">101</xref>]. The central domain of ERCC1 binds to TPR motifs 1, 2, 3, and 6 in FANCG; the C-terminal domain of XPF binds to ERCC1 [<xref ref-type="bibr" rid="B115">115</xref>&#x2013;<xref ref-type="bibr" rid="B118">118</xref>]. XPF then creates an incision at the site of the ICL leading to unhooking of the ICL [<xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B103">103</xref>]. Another endonuclease, SLX4/FANCP is also involved in the incision process and aids in protein coordination [<xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B104">104</xref>, <xref ref-type="bibr" rid="B128">128</xref>, <xref ref-type="bibr" rid="B129">129</xref>]. Thus, &#x3b1;SpII recognizes and binds to DNA at sites of ICLs and acts as a scaffold in recruitment of XPF-ERCC1 via FANCG. It then incises the DNA and is involved in the unhooking of the ICL. SLX4/FANCP is recruited and also participates in this step [<xref ref-type="bibr" rid="B104">104</xref>&#x2013;<xref ref-type="bibr" rid="B106">106</xref>]. Other FA proteins could be involved in this repair process as well.</p>
<p>After these events, DNA translesion synthesis takes place and the lesion is bypassed by a translesion DNA polymerase [<xref ref-type="bibr" rid="B58">58</xref>, <xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B124">124</xref>, <xref ref-type="bibr" rid="B125">125</xref>]. This is followed by homologous recombination and adduct removal by NER [<xref ref-type="bibr" rid="B58">58</xref>, <xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B124">124</xref>, <xref ref-type="bibr" rid="B125">125</xref>]. A large number of FA proteins take part in these steps. These stages in the repair process, which involve DNA translesion synthesis, homologous recombination and NER are discussed in detail in numerous reviews and will not be elaborated upon here [<xref ref-type="bibr" rid="B57">57</xref>&#x2013;<xref ref-type="bibr" rid="B61">61</xref>, <xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B124">124</xref>&#x2013;<xref ref-type="bibr" rid="B126">126</xref>]. The reader is directed to these reviews. Since the role of &#x3b1;SpII in ICL repair is mainly in the initial damage recognition and incision steps of the repair pathway, these are the components of the FA pathway that have been emphasized here.</p>
<p>The exact relationship between &#x3b1;SpII and FANCD2 in this repair process is not clear. Time course experiments show that &#x3b1;SpII binds to the damaged DNA after FANCD2 (<xref ref-type="fig" rid="F4">Figure 4</xref>) [<xref ref-type="bibr" rid="B49">49</xref>]. It does not colocalize with monoubiquitinated FANCD2 (FANCD2Ub) in nuclear foci nor is it required for monoubiquitination of FANCD2 after ICL damage or for its localization to sites of damage [<xref ref-type="bibr" rid="B49">49</xref>]. Monoubiquitination of FANCD2 is not required for binding of &#x3b1;SpII to damaged DNA [<xref ref-type="bibr" rid="B49">49</xref>]. The time course for localization of FANCD2 to nuclear foci after ICL damage is different than that of &#x3b1;SpII (<xref ref-type="fig" rid="F3">Figure 3</xref>) [<xref ref-type="bibr" rid="B49">49</xref>]. FANCD2 foci first appear 2&#xa0;h after ICL damage, increase up until 16&#xa0;h, remain fairly stable until 24&#xa0;h and are still present at 72&#xa0;h (<xref ref-type="fig" rid="F3">Figure 3</xref>) [<xref ref-type="bibr" rid="B49">49</xref>]. In contrast, &#x3b1;SpII foci first appear 10&#xa0;h after DNA ICL formation, peak at 16&#xa0;h and disappear by 24&#xa0;h [<xref ref-type="bibr" rid="B49">49</xref>]. Thus, FANCD2-Ub associates in foci with damaged DNA before &#x3b1;SpII foci appear and is still present when &#x3b1;SpII foci are gone [<xref ref-type="bibr" rid="B49">49</xref>]. The time course of FANCD2 foci corresponds to that of formation of &#x263;H2AX (phosphorylated histone H2A) foci which localize to sites of DNA double strand breaks (<xref ref-type="fig" rid="F3">Figure 3</xref>) [<xref ref-type="bibr" rid="B49">49</xref>]. Both FANCD2 and &#x263;H2AX foci are present 72&#xa0;h after damage, which could indicate additional involvement of FANCD2 in later stages in the ICL repair process as has been proposed [<xref ref-type="bibr" rid="B49">49</xref>, <xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B136">136</xref>]. The relationship between &#x3b1;SpII and ubiquitinated FANCD2 needs to be further explored.</p>
<p>In human cells, &#x3b1;SpII is also needed for the localization of FANCA and FANCF to sites of ICL damage [<xref ref-type="bibr" rid="B43">43</xref>]. FANCA and FANCF do not localize to nuclear foci after ICL damage if &#x3b1;SpII has been knocked down by siRNA [<xref ref-type="bibr" rid="B45">45</xref>]. Whether this colocalization of FANCA and FANCF with &#x3b1;SpII and XPF at damage sites is a component of the recruitment of the FA core complex to sites of DNA damage or is a component of the steps involved in the unhooking of the DNA ICL is not clear and needs to be further investigated.</p>
</sec>
</sec>
<sec id="s7">
<title>Importance of &#x3bc;-calpain and FA proteins in the regulation of cleavage of &#x3b1;SpII in FA cells</title>
<p>The importance of &#x3b1;SpII stability in DNA repair is seen in cells from patients with Fanconi anemia (FA) which, as mentioned above, are defective in ability to repair DNA ICLs [<xref ref-type="bibr" rid="B43">43</xref>&#x2013;<xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B51">51</xref>&#x2013;<xref ref-type="bibr" rid="B61">61</xref>]. Of significance, Lambert et. al. have shown that there is a deficiency in &#x3b1;SpII in cells from patients from a number of FA complementation groups [<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B69">69</xref>]. Levels of &#x3b1;SpII are 35&#x2013;40% of those found in normal human cells [<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B45">45</xref>]. This deficiency correlates with reduced levels of repair of DNA ICLs in FA cells which are 35&#x2013;45% of normal [<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B48">48</xref>]. Levels of DNA repair after DNA ICL damage were determined in FA-A, FA-C, FA-D2, FA-F and FA-G cells by measurement of unscheduled DNA synthesis (UDS), which measures uptake of nucleotides into DNA repair patches [<xref ref-type="bibr" rid="B47">47</xref>].</p>
<p>An important question is, what is the cause of the reduced levels of &#x3b1;SpII in FA cells? Lambert et al have shown that this is not due to reduced expression of &#x3b1;SpII, since FA cells express normal levels of &#x3b1;SpII mRNA [<xref ref-type="bibr" rid="B70">70</xref>]. They have demonstrated that it is due to increased cleavage of &#x3b1;SpII as a result of excessive activity of the protease, &#x3bc;calpain, which cleaves &#x3b1;SpII [<xref ref-type="bibr" rid="B69">69</xref>]. They have proposed that FA proteins play a critical role in regulation of &#x3bc;-calpain cleavage of &#x3b1;SpII and that reduced levels of FA proteins in FA cells leads to increased &#x3bc;-calpain activity and increased cleavage of &#x3b1;SpII [<xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B69">69</xref>]. Thus, both increased &#x3bc;-calpain activity and reduced levels of FA proteins are proposed to play a critical role in the breakdown of &#x3b1;SpII that occurs in FA cells and the reduction in DNA repair. These points and their significance will be discussed below.</p>
<sec id="s7-1">
<title>Excessive &#x3bc;-calpain activity in FA cells leads to increased cleavage of &#x3b1;SpII and decreased DNA ICL repair</title>
<p>Within the cell, &#x3b1;SpII is susceptible to cleavage by the protease, &#x3bc;-calpain [<xref ref-type="bibr" rid="B75">75</xref>, <xref ref-type="bibr" rid="B132">132</xref>&#x2013;<xref ref-type="bibr" rid="B134">134</xref>]. &#x3b1;SpII is cleaved by &#x3bc;-calpain at a single site, Y<sub>1176</sub>-G<sub>1177</sub>, which is adjacent to the SH3 domain of &#x3b1;SpII (<xref ref-type="fig" rid="F5">Figure 5</xref>) [<xref ref-type="bibr" rid="B75">75</xref>, <xref ref-type="bibr" rid="B76">76</xref>]. Proteolysis of &#x3b1;SpII by &#x3bc;-calpain leads to destabilization of the spectrin scaffold and the physiological processes and pathways it regulates [<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B75">75</xref>, <xref ref-type="bibr" rid="B76">76</xref>, <xref ref-type="bibr" rid="B89">89</xref>]. Susceptibility of &#x3b1;SpII to proteolytic cleavage is controlled by phosphorylation/dephosphorylation of residue Y1176 in &#x3bc;-calpain&#x2019;s cleavage site [<xref ref-type="bibr" rid="B75">75</xref>, <xref ref-type="bibr" rid="B76">76</xref>]. When residue Y1176 is phosphorylated by c-Src, a kinase that binds to the SH3 domain of &#x3b1;SpII, &#x3bc;-calpain cannot cleave &#x3b1;SpII at its cleavage site [<xref ref-type="bibr" rid="B75">75</xref>, <xref ref-type="bibr" rid="B76">76</xref>]. Binding of low-molecular weight phosphotyrosine phosphatase (LMW-PTP) to the SH3 domain of &#x3b1;SpII leads to dephosphorylation of Y1176 and allows &#x3bc;-calpain to cleave &#x3b1;SpII at this site (<xref ref-type="fig" rid="F5">Figure 5</xref>) [<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B75">75</xref>]. Thus, inhibiting the binding of LMW-PTP to the SH3 domain of &#x3b1;SpII and the subsequent dephosphorylation of Y1176 is important in preventing cleavage of &#x3b1;SpII by &#x3bc;-calpain. In normal physiological processes, a balance is reached between activation of &#x3bc;-calpain and substrate-level regulation of &#x3b1;SpII cleavage [<xref ref-type="bibr" rid="B75">75</xref>, <xref ref-type="bibr" rid="B76">76</xref>, <xref ref-type="bibr" rid="B135">135</xref>]. This balance depends on maintaining an equilibrium between binding of c-Src and LMW- PTP to the SH3 domain of &#x3b1;SpII, phosphorylation/dephosphorylation of the Y1176 residue and the accessibility of the &#x3bc;-calpain cleavage site to cleavage by &#x3bc;-calpain [<xref ref-type="bibr" rid="B75">75</xref>, <xref ref-type="bibr" rid="B76">76</xref>].</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>A proposed model for the role of FA proteins in maintenance of stability of &#x3b1;SpII in cells and regulation of its cleavage by &#xb5;-calpain. FANCG is used as an example of a FA protein in this process. A segment of &#x3b1;SpII containing repeats 8&#x2013;11 is represented. <bold>(A)</bold> In normal human cells, an equilibrium exists between low molecular weight phosphotyrosine phosphatase (PTP), FANCG, and c-Src for binding to the SH3 domain of &#x3b1;SpII in repeat 10. When c-Src binds to the SH3 domain of &#x3b1;SpII, it phosphorylates Tyr<sup>1176</sup> (Y1176) at the adjacent &#xb5;-calpain cleavage site. This prevents the ability of &#xb5;-calpain to cleave &#x3b1;SpII at its cleavage site. When FANCG binds to the SH3 domain, it prevents PTP binding at this site and &#x03BC;-calpain cleavage of &#x03B1;SpII. FANCG could also bind to &#xb5;-calpain and inhibit its ability to cleave &#x3b1;SpII at this site. In both instances, the inability of &#xb5;-calpain to cleave &#x3b1;SpII would enhance the stability of &#x3b1;SpII in the cell. <bold>(B)</bold> In FA cells (FA-G cells for example), a functional FANCG protein is absent and not available for binding to the SH3 domain of &#x3b1;IISp or to &#xb5;-calpain. There would be a greater probability that PTP would bind to the SH3 domain. This would lead to the dephosphorylation of Y1176 and allow &#xb5;-calpain to cleave &#x3b1;SpII at its cleavage site. FANCG would also not be present to bind to &#xb5;-calpain and inhibit its activity. Thus, as is found in FA-G cells, there would be greater cleavage of &#x3b1;IISp. Similar events could occur in different FA complementation groups (e.g., FA-A). (Modified from Zhang et al., [<xref ref-type="bibr" rid="B69">69</xref>] with permission from the American Chemical Society).</p>
</caption>
<graphic xlink:href="ebm-250-10537-g005.tif"/>
</fig>
<p>In FA cells, Lambert et al have shown that in a number of complementation groups (FA-A, FA-C, FA-D2, FA-F, and FA-G) &#x3bc;-calpain activity is 3-4 fold greater than it is in normal cells (<xref ref-type="fig" rid="F6">Figure 6</xref>) [<xref ref-type="bibr" rid="B69">69</xref>]. This is not due to an increase in protein levels of &#x3bc;-calpain, which are similar to those in normal cells, but to the significantly increased activity of &#x3bc;-calpain [<xref ref-type="bibr" rid="B69">69</xref>]. The excessive activation of &#x3bc;-calpain activity in FA cells is demonstrated by the presence of the characteristic 150&#xa0;kDa break-down product of &#x3b1;SpII which is produced by &#x3bc;-calpain proteolytic cleavage of &#x3b1;SpII [<xref ref-type="bibr" rid="B69">69</xref>, <xref ref-type="bibr" rid="B132">132</xref>, <xref ref-type="bibr" rid="B140">140</xref>, <xref ref-type="bibr" rid="B141">141</xref>]. This break-down product is relatively stable and widely used as a measure of &#x3bc;-calpain cleavage of &#x3b1;SpII [<xref ref-type="bibr" rid="B141">141</xref>]. The increase in &#x3bc;-calpain activity in FA cells correlates with decreased levels of &#x3b1;SpII, which are approximately 35&#x2013;40% of those found in normal cells [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B44">44</xref>]. That FA proteins play an important role in modulating the levels of &#xb5;-calpain activity found in normal cells is demonstrated by the finding that restoring levels of FA proteins in FA cells to those found in normal cells by transfection of FA cells with a retroviral vector expressing the appropriate FANC cDNA leads to reduction of &#xb5;-calpain activity to normal levels (<xref ref-type="fig" rid="F6">Figure 6</xref>) [<xref ref-type="bibr" rid="B69">69</xref>].</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>&#xb5;-Calpain activity in FA cells. &#xb5;-Calpain activity was measured in FA-A, FA-C, FA-D2, FA-F and FA-G cells, in corrected FA-A (FA-A&#x2b;), FA-C (FA-C&#x2b;), and FA-G (FA-G&#x2b;) cells which had been stably transfected with a retroviral vector expressing the appropriate FANC cDNA, and in normal cells. Comparison of &#xb5;-calpain activity between the groups of cells showed that &#xb5;-calpain activity was 3-4 fold greater in FA cells compared to normal cells or corrected FA cells. Activity was determined by measuring cleavage of a fluorogenic calpain substrate and expressed as relative fluorescence units (RFU). Vertical lines represent &#xb1; the standard error of the mean for 5&#x2013;8 separate experiments (&#x2a;) (p &#x3c; 0.0001). (Reproduced from Zhang et al., [<xref ref-type="bibr" rid="B69">69</xref>] with permission from the American Chemical Society).</p>
</caption>
<graphic xlink:href="ebm-250-10537-g006.tif"/>
</fig>
<p>Evidence that &#x3b1;SpII cleavage in FA cells is due to increased &#x3bc;-calpain activity is demonstrated by studies which show that in FA-A cells after knockdown of &#x3bc;-calpain by siRNA and damage with MMC or 8-MOP plus UVA light, &#x3b1;SpII levels are restored to normal and damage-induced &#x3b1;SpII nuclear foci are observed (<xref ref-type="fig" rid="F7">Figure 7</xref>) [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B69">69</xref>]. XPF co-localizes with SpII in these foci just as it does in normal cells [<xref ref-type="bibr" rid="B69">69</xref>]. This is indicative of DNA ICL repair. In addition, there is a decrease in the chromosomal abnormalities (chromatid beaks, inter chromatid exchanges, chromatid fusions and radial formations) observed in FA cells after DNA ICL damage [<xref ref-type="bibr" rid="B69">69</xref>]. Thus, there is strong evidence that increased cleavage of &#x3b1;SpII in FA cells is due to excessive activation of &#x3bc;-calpain in these cells.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>Effect of siRNA knock down of &#xb5;-calpain in FA cells on formation of &#x3b1;SpII and XPF nuclear foci after damage with an ICL agent, MMC. <bold>(A)</bold> FA-A and normal cells were transfected with non-target siRNA (&#x2212;) or &#xb5;-calpain siRNA (&#x2b;) and 24&#xa0;h after transfection, cells were either undamaged or treated with MMC. &#x3b1;SpII and XPF nuclear foci were examined 16&#xa0;h after MMC treatment using indirect immunofluorescence and staining with anti-&#x3b1;SpII or anti-XPF. After &#xb5;-calpain knock down, &#x3b1;SpII levels in FA-A cells were returned to normal levels and &#x3b1;SpII and XPF localized to damage-induced nuclear foci. <bold>(B)</bold> There was no significant difference in the percentage of nuclei showing multiple foci in FA-A cells in which &#xb5;-calpain had been knocked down compared to normal cells transfected with either Nt siRNA or &#xb5;-calpain siRNA (Reproduced from Zhang et al., [<xref ref-type="bibr" rid="B69">69</xref>] with permission from the American Chemical Society).</p>
</caption>
<graphic xlink:href="ebm-250-10537-g007.tif"/>
</fig>
<p>Of particular interest, excessive activation of calpain activity also occurs in a number of neurodegenerative diseases and has been proposed to contribute to the neuropathology of many of these disorders [<xref ref-type="bibr" rid="B135">135</xref>]. This excessive activation correlates with a loss of SpII and has been proposed to be associated with the clinical manifestations of these disorders [<xref ref-type="bibr" rid="B132">132</xref>, <xref ref-type="bibr" rid="B135">135</xref>, <xref ref-type="bibr" rid="B140">140</xref>, <xref ref-type="bibr" rid="B141">141</xref>]. Excessive activation of calpain and is also found in cancer development [<xref ref-type="bibr" rid="B132">132</xref>, <xref ref-type="bibr" rid="B135">135</xref>, <xref ref-type="bibr" rid="B140">140</xref>, <xref ref-type="bibr" rid="B141">141</xref>]. FA may be another example of a disorder in which &#x3b1;SpII breakdown by excessive calpain activity plays an important role in the pathological manifestations of the disorder. This will be discussed in a later section.</p>
</sec>
<sec id="s7-2">
<title>FA proteins play a critical role in reducing cleavage and maintaining the stability of &#x3b1;SpII in cells</title>
<p>FA proteins are proposed to play a critical role in maintenance of &#x3b1;SpII stability and regulation of its cleavage in the cell [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B69">69</xref>]. In support of this, in corrected FA cells (FA-A, FA-C, and FA-G) which have been stably transduced with a retroviral vector expressing the appropriate FANC cDNA (FANCA, FANCC, or FANCG), FA protein levels return to those found in normal cells, as do the levels of &#x3b1;SpII [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B69">69</xref>]. In these corrected FA cells, &#x3bc;-calpain activity is also at normal levels (<xref ref-type="fig" rid="F6">Figure 6</xref>) [<xref ref-type="bibr" rid="B69">69</xref>]. Lambert et al have proposed several mechanisms by which FA proteins could aid in maintenance of &#x3b1;SpII stability in the cell and regulation of its cleavage by &#x3bc;-calpain [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B69">69</xref>]. One of these is that a FA protein binds to the SH3 domain of &#x3b1;SpII and inhibits the ability of LMW-PTP to bind to the site and dephosphorylate it at Y1176. This, in turn, would prevent the ability of &#x3bc;calpain to cleave &#x3b1;SpII at its cleavage site and would enhance the stability of &#x3b1;SpII (<xref ref-type="fig" rid="F5">Figure 5A</xref>). In support of this, FANCG has been shown to have a 1@ consensus sequence that directly binds to the SH3 domain of &#x3b1;SpII [<xref ref-type="bibr" rid="B101">101</xref>]. This binding could be constitutive. FANCG could exist in equilibrium with c-Src and LMW-PTP for binding to this site. Since affinity of ligands that bind to SH3 domains, in particular the SH3 domain of &#x3b1;SpII, is quite low, the on and off binding rates can be fast, allowing a rapid exchange in binding of these proteins [<xref ref-type="bibr" rid="B79">79</xref>, <xref ref-type="bibr" rid="B81">81</xref>]. Importantly, there are a number of patient derived mutations in the <italic>FANCG</italic> gene that result in FANCG having a defect or loss in the consensus sequence that binds to the SH3 domain of &#x3b1;SpII [<xref ref-type="bibr" rid="B101">101</xref>]. This could lead to loss of ability of FANCG to bind to &#x3b1;SpII [<xref ref-type="bibr" rid="B101">101</xref>]. This would provide LMW-PTP greater accessibility to the SH3 domain and lead to greater cleavage of &#x3b1;SpII by &#x3bc;-calpain (<xref ref-type="fig" rid="F5">Figure 5B</xref>). FA-G patients have a poorer hematological outcome than patients from other FA complementation groups due to a more severe cytopenia and a higher incidence of AML and leukemia [<xref ref-type="bibr" rid="B67">67</xref>, <xref ref-type="bibr" rid="B142">142</xref>]. It would be of interest to determine if this is related to the inability of a defective FANCG to bind to &#x3b1;SpII and aid in preventing excessive cleavage of &#x3b1;SpII by &#x3bc;-calpain, and in maintaining the stability of &#x3b1;SpII in FA-G cells.</p>
<p>Another possible mechanism by which FA proteins could regulate &#x3bc;-calpain activity and cleavage of &#x3b1;SpII is that a FA protein binds to &#x3bc;-calpain and prevents its ability to cleave &#x3b1;SpII. Supporting this is yeast two-hybrid analysis which has shown that FANCA and FANCG bind directly to &#x3bc;-calpain [<xref ref-type="bibr" rid="B69">69</xref>]. This binding could potentially inhibit &#x3bc;calpain&#x2019;s activity. Alternatively, a FA protein could bind to &#x3b1;SpII, protecting the &#x3bc;-calpain cleavage site from attack by &#x3bc;-calpain. A fourth potential mechanism is that a FA protein could have an effect on the binding of calmodulin to &#x3b1;SpII. Calmodulin binds to &#x3b1;SpII at a site adjacent to &#x3bc;-calpain&#x2019;s cleavage site and enhances the susceptibility of &#x3b1;SpII to cleavage by &#x3bc;-calpain [<xref ref-type="bibr" rid="B82">82</xref>&#x2013;<xref ref-type="bibr" rid="B84">84</xref>]. A FA protein, in some manner, could interfere with this binding of calmodulin to &#x3b1;SpII and inhibit its ability to stimulate &#x3bc;-calpain&#x2019;s cleavage of &#x3b1;SpII. In FA cells, a defect in a specific FA protein could lead to enhanced binding of calmodulin to &#x3b1;SpII and enhanced cleavage by &#x3bc;-calpain. FA proteins also bind to each other, particularly those in the FA core group (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, and FANCL) [<xref ref-type="bibr" rid="B143">143</xref>]. For example, FANCG binds directly to FANCF [<xref ref-type="bibr" rid="B143">143</xref>]. It is possible that such interactions could aid in association of FA proteins with &#x3b1;SpII.</p>
<p>There are thus a number of potential mechanisms by which FA proteins could play an important role in regulating the activity of &#x3bc;-calpain and its ability to cleave &#x3b1;SpII. Different FA proteins could affect a different aspect of the &#x3b1;SpII cleavage process, either directly or indirectly. The stability of &#x3b1;SpII is a critical component in the DNA ICL repair process and excessive cleavage of &#x3b1;SpII in FA cells by &#x3bc;-calpain is proposed to be an important factor in the DNA repair deficiency in these cells [<xref ref-type="bibr" rid="B69">69</xref>]. Lambert et al. have proposed that FA proteins play a significant role in the regulation of &#x3b1;SpII cleavage and its stability in the cell [<xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B69">69</xref>]. The exact mechanisms by which this occurs needs to be investigated further.</p>
<p>These studies demonstrate another important role for FA proteins in the cell and in the DNA repair process. In addition to the role FA proteins play in DNA ICL repair, it is proposed that they also act as regulators of the cleavage of &#x3b1;SpII by &#x3bc;-calpain. This could be important for a large number of cellular processes in which &#x3b1;SpII is required, loss of which could lead to chromosome instability, DNA repair defects, congenital and developmental abnormalities, progression of cancer, neuronal degeneration and neurological disorders, which are characteristics of FA.</p>
</sec>
</sec>
<sec id="s8">
<title>&#x3b1;SpII is critical for maintenance of telomere function and chromosome stability after DNA ICL damage</title>
<sec id="s8-1">
<title>&#x3b1;SpII recruits repair proteins to telomeres after DNA ICL damage</title>
<p>Telomeres are critical for maintenance of chromosome stability and after DNA damage &#x3b1;SpII plays a major role in this process [<xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B144">144</xref>&#x2013;<xref ref-type="bibr" rid="B150">150</xref>]. Lambert et al have demonstrated that &#x3b1;SpII is recruited to telomeres in S phase after DNA ICL damage and is critical for the repair of telomeric DNA at the time when telomeres are undergoing DNA replication [<xref ref-type="bibr" rid="B46">46</xref>]. &#x3b1;SpII co-localizes with a telomere-specific Cy [<xref ref-type="bibr" rid="B3">3</xref>]-labeled nucleic acid (PNA) oligonucleotide probe and with two proteins in the shelterin complex, TRF1 and TRF2, which help protect the telomere and prevent telomere dysfunction (<xref ref-type="fig" rid="F8">Figure 8</xref>) [<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B50">50</xref>]. These studies were carried out in normal human lymphoblastoid cells which have telomerase, a ribonucleoprotein complex important in maintaining the ends of chromosomes [<xref ref-type="bibr" rid="B148">148</xref>, <xref ref-type="bibr" rid="B151">151</xref>&#x2013;<xref ref-type="bibr" rid="B153">153</xref>]. Telomerase positive cells were used since telomerase is present in a number of the cell types involved in the clinical manifestations of FA (e.g., highly proliferating cells, bone marrow cells, peripheral blood cells, stem cells which include hematopoietic stem cells, and numerous types of cancer cells) [<xref ref-type="bibr" rid="B154">154</xref>, <xref ref-type="bibr" rid="B155">155</xref>]. These studies have demonstrated that &#x3b1;SpII acts as a scaffold and recruits XPF to sites of ICL damage on telomeric DNA in normal human cells, indicating that it aids in repair of the ICL damage in telomeres [<xref ref-type="bibr" rid="B46">46</xref>]. Knock down of &#x3b1;SpII in normal cells leads to loss of localization of XPF to sites of damage on telomeric DNA, demonstrating that &#x3b1;SpII is critical in this recruitment process (<xref ref-type="fig" rid="F9">Figure 9A</xref>) [<xref ref-type="bibr" rid="B46">46</xref>]. In FA-A cells, in which there is a deficiency in &#x3b1;SpII, XPF, though present, does not form foci at sites of ICLs on telomeric DNA (<xref ref-type="fig" rid="F9">Figure 9A</xref>). After &#x3b1;SpII levels are restored to normal by knocking down &#xb5;-calpain, XPF localizes to sites of damage on telomeres (<xref ref-type="fig" rid="F9">Figure 9B</xref>) [<xref ref-type="bibr" rid="B46">46</xref>]. This emphasizes the importance of &#x3b1;SpII in localization of XPF to damage sites on telomeres.</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>&#x3b1;SpII associates with telomeres after DNA ICL damage. <bold>(A)</bold> &#x3b1;SpII associates with a Cy3-labeled telomere specific probe (PNA) as well as two telomeric proteins in the shelterin complex, TRF1 and TRF2, after 16&#xa0;h treatment with MMC. Cells were examined using a PNS probe as well as immunoFISH and staining with antispectrin, anti-TRF1 or anti-TRF2 antibodies. Nuclear DNA was counterstained with DAPI. Pictures were taken with Z-stack and one slice is displayed. Magnified images are shown of co-localization of &#x3b1;SpII with (a) PNA probe; (b) TRF1 and (c) TRF2. <bold>(B)</bold> The number of &#x3b1;SpII nuclear foci per cell and the number of &#x3b1;SpII foci that co-localized with PNA, TRF1 and TRF2 foci per cell in normal cells before and after MMC treatment was quantitated. Three hundred cells were counted in each group. Error bars represent SEM. (Modified from Zhang et al., [<xref ref-type="bibr" rid="B46">46</xref>] with permission of Oxford University Press).</p>
</caption>
<graphic xlink:href="ebm-250-10537-g008.tif"/>
</fig>
<fig id="F9" position="float">
<label>FIGURE 9</label>
<caption>
<p>&#x3b1;SpII is needed for recruitment of XPF to sites of ICL damage on telomeric DNA. <bold>(A)</bold> In normal cells transfected with Nt siRNA and treated with MMC for 16 h, XPF co-localized with TRF1. A magnified image of co-localization of XPF with TRF1 in MMC-treated Nt-siRNA-transfected cells is shown to the right. Knock-down of &#x3b1;SpII in normal cells leads to loss of localization of XPF with TRF1 at telomeres after cells are treated with MMC. These studies were carried out using immunoFISH and staining with antiXPF and anti-TRF1 antibodies. Nuclear DNA is counterstained with DAPI. <bold>(B)</bold> In FA-A cells, XPF does not form foci in the nucleus after ICL damage. However, in FA-A cells in which &#x3bc;-calpain (&#x3bc;-cal) had been knocked down with &#x3bc;-calpain siRNA and cells were subsequently treated with MMC, XPF co-localized with TRF1 at telomeres. A magnified image of co-localization of XPF with TRF1 in FA-A cells in which &#x3bc;-calpain had been knocked down and then treated with MMC is shown on the right. <bold>(C)</bold> The number of XPF nuclear foci and XPF nuclear foci which colocalized with TRF1 was quantitated in normal and FA-A cells. These numbers were the same between normal cells transfected with Nt-siRNA and FA-A cells transfected with &#x3bc;-calpain siRNA, both of which had been treated with MMC. (Reproduced from Zhang et al., [<xref ref-type="bibr" rid="B46">46</xref>] with permission of Oxford University Press).</p>
</caption>
<graphic xlink:href="ebm-250-10537-g009.tif"/>
</fig>
<p>There are differences, however, in the repair events in telomeric DNA compared to non-telomeric DNA. Studies have shown that, in normal human lymphoblastoid cells and HeLa cells, both of which express telomerase, FANCD2, unlike &#x3b1;SpII, does not localize in foci in telomeric DNA after ICL damage [<xref ref-type="bibr" rid="B46">46</xref>]. FANCD2 was found, however, to localize to telomeres in immortalized telomerase-negative cells after DNA ICL damage [<xref ref-type="bibr" rid="B156">156</xref>]. These studies thus indicate that in telomerase-positive cells FANCD2 is not involved in repair of DNA ICLs at telomeres, however, it is involved in ICL repair in telomeres in telomerase-negative cells. It is possible that, in telomerase-positive cells, the repair response to DNA ICLs is similar to, but not identical to, that which occurs in genomic, non-telomeric, DNA. This needs to be explored further.</p>
</sec>
<sec id="s8-2">
<title>Dramatic reduction of &#x3b1;SpII levels in cells leads to catastrophic loss of telomeres and chromosomal aberrations after DNA ICL damage</title>
<p>The importance of &#x3b1;SpII in repair of DNA ICLs in telomeric DNA is supported by studies which have demonstrated that, in normal human cells in which &#x3b1;SpII has been knocked-down to levels that are 35% of normal and which have been damaged with a DNA ICL agent, there is telomere dysfunction, as evidenced by the increased formation of telomere dysfunction-induced foci (TIF) [<xref ref-type="bibr" rid="B46">46</xref>]. These foci represent sites of DNA doublestrand breaks (DSBs), which arise when the DNA replication forks are stalled at the site of a DNA ICL, and are an indicator of dysfunctional telomeres [<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B157">157</xref>, <xref ref-type="bibr" rid="B158">158</xref>]. It has been proposed that decreased levels of &#x3b1;SpII can lead to stalling of replication of telomeric DNA at sites of DNA ICLs in S phase [<xref ref-type="bibr" rid="B46">46</xref>]. This results in collapse of the replication fork and in the formation of DNA DSBs which are measured by determining the accumulation at telomeres of &#x263;H2AX foci, which are markers for DSBs. In addition to increased TIF formation, knock-down of &#x3b1;SpII also leads to catastrophic loss of telomeres after DNA ICL damage (<xref ref-type="fig" rid="F10">Figure 10</xref>) [<xref ref-type="bibr" rid="B46">46</xref>]. This loss can be determined by examination of chromosomes for loss of telomeres or production of signal free ends (SFEs) (<xref ref-type="fig" rid="F10">Figure10</xref>) [<xref ref-type="bibr" rid="B46">46</xref>]. Since DNA replication in telomeres occurs in S phase, and &#x3b1;SpII localizes to telomeres in S phase after ICL damage, this suggests that &#x3b1;SpII is important in telomere function during replication of ICL-damaged DNA. A loss of &#x3b1;SpII could thus have significant effects on DNA replication after ICL damage and could lead to production of stalled replication forks. If &#x3b1;SpII is not recruited to these stalled replication forks to aid in repair of the DNA damage, it can be hypothesized that this could lead to failure to efficiently restart replication and to telomere dysfunction and loss of telomeres. These studies demonstrate the importance of &#x3b1;SpII in telomere maintenance and function after DNA ICL damage.</p>
<fig id="F10" position="float">
<label>FIGURE 10</label>
<caption>
<p>A deficiency in &#x3b1;SpII in cells leads to a catastrophic loss of telomeres after DNA ICL damage. In normal human cells in which &#x3b1;SpII has been knocked down by siRNA, there is a loss of telomeres after treatment with a DNA ICL agent, MMC, compared to normal cells transfected with a Nt siRNA [<xref ref-type="bibr" rid="B46">46</xref>]. This is noted by the presence of signal free ends (SFEs) on the chromosomes. In FA-A cells, after damage with MMC, there is a catastrophic loss of telomeres, as noted by the presence of (SFEs), compared to the presence of telomeres on undamaged Nt siRNA transfected FA-A cells [<xref ref-type="bibr" rid="B46">46</xref>]. However, in FA-A cells after &#xb5;-calpain has been knocked down by siRNA so as to increase &#x3b1;SpII levels, and subsequent treatment with MMC, quantitation of the frequency of SFE in chromosomes showed that it was reduced to levels similar to those in normal cells transfected with Nt siRNA. These studies demonstrate that &#x3b1;SpII has a critical role in maintaining telomere function after damage with a DNA ICL agent [<xref ref-type="bibr" rid="B46">46</xref>]. Metaphase chromosomes were stained with DAPI (blue) [<xref ref-type="bibr" rid="B46">46</xref>]. Telomeric DNA was identified using FISH with a Cy3-labeled telomere specific PNA probe (red) [<xref ref-type="bibr" rid="B46">46</xref>]. Error bars are S.E.M. &#x2a;&#x2a;&#x2a;<italic>P</italic> &#x3c; 0.0001 (Modified from Zhang et al. [<xref ref-type="bibr" rid="B46">46</xref>] with permission from Oxford University Press).</p>
</caption>
<graphic xlink:href="ebm-250-10537-g010.tif"/>
</fig>
<p>Since chromosome stability depends on functioning telomeres, it is critical that after DNA damage the damage is repaired so that chromosome integrity can be preserved. In normal cells in which &#x3b1;SpII has been knocked down, there is a significant increase in chromosomal aberrations, after DNA ICL damage, which accompanies the decrease in DNA repair that occurs in both non-telomeric and telomeric DNA [<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B69">69</xref>]. These aberrations include: chromatid breaks, sister chromatid end-to-end fusions, radials, and chromosome exchanges [<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B69">69</xref>]. This thus demonstrates that, after DNA ICL damage, &#x3b1;SpII in both non-telomeric and telomeric DNA is critical for maintenance of not only telomere function but also chromosomal stability.</p>
</sec>
</sec>
<sec id="s9">
<title>Telomere dysfunction in FA cells after DNA ICL</title>
<p>FA serves as an excellent model for the effects that a deficiency in &#x3b1;SpII has on telomere function after DNA damage. As mentioned above, levels of &#x3b1;SpII in FA-A cells are approximately 35&#x2013;40% of normal [<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B48">48</xref>]. Telomere dysfunction has been observed in FA complementation group A (FA-A) cells after DNA ICL (i.e., MMC or psoralen plus UVA light) damage [<xref ref-type="bibr" rid="B46">46</xref>]. This includes a significant increase in TIF formation and a catastrophic loss of telomeres (<xref ref-type="fig" rid="F10">Figure 10</xref>) [<xref ref-type="bibr" rid="B46">46</xref>]. This increase correlates with loss of &#x3b1;SpII in these cells, which results in a significant decrease in recruitment of XPF to sites of damage at telomeres as mentioned above (<xref ref-type="fig" rid="F9">Figure 9A</xref>) [<xref ref-type="bibr" rid="B46">46</xref>]. These studies indicate that there is a defect in repair of ICLs at telomeres in FA-A cells similar to that seen in normal cells after &#x3b1;SpII has been knocked down.</p>
</sec>
<sec id="s10">
<title>Knock-down of &#x3bc;-calpain in FA-A cells corrects the &#x3b1;SpII deficiency, telomere dysfunction, defective DNA repair and chromosome instability after DNA ICL damage</title>
<p>Evidence that loss of &#x3b1;SpII in FA-A cells is a significant factor in the increase in telomere dysfunction and in the catastrophic loss of telomeres that occurs after DNA ICL damage is demonstrated by studies in which &#x3bc;-calpain has been knocked down by siRNA. Knock down of &#x3bc;-calpain in FA-A cells leads to restoration of &#x3b1;SpII levels to those found in normal cells and to reduction in the number of TIF positive cells after MMC treatment [<xref ref-type="bibr" rid="B46">46</xref>]. In addition, it also results in a significant decrease in the frequency of signal-free ends (SFEs) or telomere loss in FA-A cells after DNA ICL damage (<xref ref-type="fig" rid="F10">Figure 10</xref>) [<xref ref-type="bibr" rid="B46">46</xref>]. These studies thus demonstrate that breakdown of &#x3b1;SpII in FA-A cells due to excessive &#x3bc;-calpain activity results in telomere dysfunction and loss of telomeres, which can be corrected by knocking-down &#x3bc;-calpain.</p>
<p>In FA-A cells, unlike in normal cells, XPF does not localize to telomeres after DNA ICL damage (<xref ref-type="fig" rid="F9">Figure 9B</xref>) [<xref ref-type="bibr" rid="B46">46</xref>]. However, when &#x3bc;-calpain is knocked down by siRNA and &#x3b1;SpII levels have been restored to normal, XPF co-localizes with &#x3b1;SpII in damage induced foci at telomeres (<xref ref-type="fig" rid="F9">Figure 9B</xref>) [<xref ref-type="bibr" rid="B46">46</xref>]. These studies again demonstrate that &#x3b1;SpII plays a critical role in telomere function after DNA ICL damage, and that restoration of &#x3b1;SpII to normal levels in FA cells by knocking down &#x3bc;-calpain can have a significant effect on increasing the DNA repair capability of these cells and correcting the telomere dysfunction observed after DNA ICL damage [<xref ref-type="bibr" rid="B46">46</xref>].</p>
<p>Chromosomal aberrations produced after DNA ICL damage are also corrected in FA cells after restoration of &#x3b1;SpII levels to normal by knocking-down &#x3bc;-calpain [<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B46">46</xref>]. The aberrations which were corrected include sister chromatid end-to-end fusions, chromosome exchanges, and chromatid breaks and radials and are similar to those produced after ICL damage in normal cells in which &#x3b1;SpII levels have been knocked down [<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B46">46</xref>]. Thus decreasing &#x3bc;-calpain activity in FA cells and restoring &#x3b1;SpII levels to normal leads to restoration of DNA repair capabilities, localization of XPF to sites of DNA damage, increased chromosomal stability, and a decrease in formation of dysfunctional telomeres and in loss of telomeres after DNA ICL damage. These studies indicate that both loss of &#x3b1;SpII and telomere dysfunction in FA-A cells may be important factors in the chromosomal aberrations which develop after DNA ICL damage.</p>
<p>Of particular interest, FA-A cells in which &#x3b1;SpII levels have been restored to normal are still deficient in the FANCA protein. The question that arises is how DNA ICL repair can still proceed in the absence of this protein. Lambert et. al. have proposed that FA proteins, in addition to a role in DNA repair, are also important in maintaining the stability of &#x3b1;SpII and reducing its cleavage by &#x3bc;-calpain [<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B69">69</xref>]. When &#x3b1;SpII stability has been restored in FA-A cells by knocking-down &#x3bc;-calpain, DNA repair is able to proceed, possibly involving an alternative means [<xref ref-type="bibr" rid="B49">49</xref>, <xref ref-type="bibr" rid="B50">50</xref>]. In FA-A cells, in which there is a deficiency in FANCA, FANCD2 is not monoubiquitinated [<xref ref-type="bibr" rid="B49">49</xref>]. FANCD2-Ub has been shown to be important for the ICL repair pathway to proceed [<xref ref-type="bibr" rid="B57">57</xref>&#x2013;<xref ref-type="bibr" rid="B59">59</xref>]. Lambert et al have shown, however, that in FA-A cells in which &#x3b1;SpII levels have been restored, non-Ub FANCD2 foci are observed at levels approximately 80% of normal just as they are in FA-A cells in which levels of &#x3b1;SpII have not been restored [<xref ref-type="bibr" rid="B49">49</xref>]. FANCD2-Ub is not present [<xref ref-type="bibr" rid="B49">49</xref>]. The non-Ub FANCD2 foci localize to sites of DNA ICL damage and the nonUb FANCD2 foci follow the same time course for formation of nuclear foci after ICL damage as the FANCD2-Ub foci do. However, in the FA-A cells non-Ub FANCD2 foci only appear after levels of &#x3b1;SpII have been returned to normal [<xref ref-type="bibr" rid="B49">49</xref>]. Thus non-Ub FANCD2 requires the presence of &#x3b1;SpII in order to localize to sites of damage. &#x3b1;SpII does not colocalize with these non-Ub FANCD2 foci, just as it does not co-localize with FANCD2- Ub foci in normal cells after DNA ICL damage [<xref ref-type="bibr" rid="B49">49</xref>]. Lambert et al have proposed that in FA-A cells when levels of &#x3b1;SpII have been returned to normal, non-Ub FANCD2 localizes to sites of damage and plays a role in the DNA repair process [<xref ref-type="bibr" rid="B49">49</xref>]. This is potentially an alternate method for DNA ICL repair. Whether this is mainly a back-up mechanism or is also involved in normal ICL repair is not clear. Other studies support the proposal that non-Ub FANCD2 plays a role in DNA ICL repair, in particular, in the nonhomologous recombination step in the repair process and in replication fork recovery [<xref ref-type="bibr" rid="B159">159</xref>&#x2013;<xref ref-type="bibr" rid="B163">163</xref>]. The relationship between &#x3b1;SpII and FANCD2-Ub and non-Ub FANCD2 after DNA damage needs to be further investigated.</p>
</sec>
<sec id="s11">
<title>Importance of loss of &#x3b1;SpII in the pathogenesis of Fanconi anemia</title>
<p>As noted above, breakdown and loss of &#x3b1;SpII in FA cells has a significant effect on both DNA repair and chromosome stability after damage with a DNA interstrand crosslinking agent. Lambert et al. have proposed that this loss is an important contributing factor in the pathogenesis of FA [<xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B44">44</xref>]. There are a number of defining characteristics associated with FA pathogenesis, the major ones of which include a defect in DNA repair, chromosome instability, cancer predisposition, bone marrow failure and multisystemic congenital abnormalities [<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B51">51</xref>&#x2013;<xref ref-type="bibr" rid="B69">69</xref>]. Experimental evidence has shown that loss of &#x3b1;SpII in FA cells has a significant impact on several of these characteristics. Breakdown of &#x3b1;SpII in FA cells has been shown to be directly involved in the defect in ability of FA cells to repair DNA ICLs [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B45">45</xref>]. Loss of &#x3b1;SpII results in failure of XPF/ERCC1 to localize to sites of DNA ICLs and create incisions at these sites leading to defective DNA ICL repair in FA cells in both telomeric and non-telomeric DNA [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B50">50</xref>]. In addition, excessive breakdown of &#x3b1;SpII in FA cells also results in chromosome instability and production of chromosomal aberrations after DNA ICL damage [<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B45">45</xref>]. It has been shown that failure to repair DNA ICLs, particularly in S phase of the cell cycle can directly lead to the production of DNA double-strand breaks and chromosomal aberrations [<xref ref-type="bibr" rid="B164">164</xref>]. This is proposed to be a major cause of chromosomal aberrations in FA cells after DNA ICL damage [<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B50">50</xref>]. Restoration of &#x3b1;SpII levels to normal in FA cells, by knocking down &#x3bc;-calpain, leads to restoration of DNA ICL repair and chromosome stability [<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B50">50</xref>]. These studies thus indicate that &#x3b1;SpII is critical for two important cellular processes, DNA repair and chromosome stability of DNA ICL damage, which are defective in FA cells and which contribute to the pathogenesis of the disorder.</p>
<p>Another phenotypic characteristic of FA is an increased incidence of cancer (e.g., acute myeloid leukemia (AML) and squamous cell carcinoma) and hemolytic anemia [<xref ref-type="bibr" rid="B67">67</xref>, <xref ref-type="bibr" rid="B68">68</xref>, <xref ref-type="bibr" rid="B77">77</xref>, <xref ref-type="bibr" rid="B165">165</xref>]. There is evidence that a deficiency in &#x3b1;SpII plays an important role in cancer development [<xref ref-type="bibr" rid="B68">68</xref>, <xref ref-type="bibr" rid="B166">166</xref>]. Loss of &#x3b1;SpII has been reported in the bone marrow of patients with acute myeloid leukemia (AML) and it has been proposed that a deficiency in &#x3b1;SpII is a contributing factor in the development of AML [<xref ref-type="bibr" rid="B165">165</xref>, <xref ref-type="bibr" rid="B167">167</xref>]. Since FA patients can develop AML, it is possible that loss of &#x3b1;SpII is an important component in this process and may be involved in the leukemogenesis and bone marrow failure which can occur [<xref ref-type="bibr" rid="B165">165</xref>, <xref ref-type="bibr" rid="B167">167</xref>]. In a number of B-cell malignant lymphomas, there is a strong correlation between loss of &#x3b1;SpII and development of lymphomagenesis [<xref ref-type="bibr" rid="B167">167</xref>]. This has led to the suggestion that a deficiency in &#x3b1;SpII is an important factor in lymphomagenesis [<xref ref-type="bibr" rid="B167">167</xref>]. Thus breakdown and loss of &#x3b1;SpII in FA cells could play a role in the development of AML and leukemogenesis observed in FA patients and contribute to FA pathogenesis. This needs to be further examined.</p>
<p>FA patients can also have a number of congenital abnormalities, which include radial ray deformities, absent radi, ear malformations, urogenital anomalies, renal deformities, cardiac defects, and neurological abnormalities [<xref ref-type="bibr" rid="B67">67</xref>, <xref ref-type="bibr" rid="B168">168</xref>, <xref ref-type="bibr" rid="B169">169</xref>]. &#x3b1;SpII has been proposed to play a role in many developmental processes [<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B170">170</xref>&#x2013;<xref ref-type="bibr" rid="B172">172</xref>]. In &#x3b1;SpII knockout mice the embryos display cardiac, craniofacial and neural tube abnormalities [<xref ref-type="bibr" rid="B170">170</xref>]. Cultured fibroblasts from these mice have impaired growth and spreading [<xref ref-type="bibr" rid="B170">170</xref>]. These studies indicate that &#x3b1;SpII is important in cellular morphology and development. Since &#x3b1;SpII is critical for and expressed throughout development in mammalian cells, it can be hypothesized that a deficiency in &#x3b1;SpII in FA patients could indirectly have a significant influence on a number of the developmental abnormalities associated with FA.</p>
</sec>
<sec id="s12">
<title>Other disorders associated with defects in &#x3b1;SpII</title>
<p>&#x3b1;SpII is an essential protein in the cell and an important cellular scaffold which is critical for a diverse number of biological processes, therefore, loss or dysfunction of this protein could be of important clinical significance and play a fundamental role in the etiology of a number of diseases [<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B13">13</xref>&#x2013;<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B25">25</xref>&#x2013;<xref ref-type="bibr" rid="B39">39</xref>]. Two important causes for a loss or deficiency in &#x3b1;SpII are: (1) enhanced cleavage and break-down of &#x3b1;SpII, or (2) mutations in the gene encoding &#x3b1;SpII, <italic>SPTAN1,</italic> resulting in expression of a defective &#x3b1;SpII. Some disorders in which defects or a deficiency in &#x3b1;SpII are of clinical significance are presented below.</p>
<p>Loss or a deficiency in &#x3b1;SpII is an important factor in the pathophysiology of a number of neurological disorders [<xref ref-type="bibr" rid="B135">135</xref>, <xref ref-type="bibr" rid="B169">169</xref>, <xref ref-type="bibr" rid="B173">173</xref>&#x2013;<xref ref-type="bibr" rid="B179">179</xref>]. Mutations in the <italic>SPTAN1</italic> gene are associated with a broad range of neurodevelopmental diseases [<xref ref-type="bibr" rid="B169">169</xref>, <xref ref-type="bibr" rid="B174">174</xref>, <xref ref-type="bibr" rid="B175">175</xref>]. One of these is early infantile epileptic encephalopathy, or West Syndrome, which is characterized by progressive brain atrophy, severe neurodevelopmental impairment, mental retardation, difficulty walking, and seizures [<xref ref-type="bibr" rid="B169">169</xref>, <xref ref-type="bibr" rid="B174">174</xref>&#x2013;<xref ref-type="bibr" rid="B177">177</xref>]. In this disorder, there is a mutation in the <italic>SPTAN1</italic> gene leading to a defect in the binding of &#x3b1;SpII to &#x3b2;SpII and to &#x3b2;SpIV, which are needed for organization and maintenance of the neuronal actin-spectrin cytoskeleton, as well as for axonal and dendritic growth and development and neuronal excitabiliity [<xref ref-type="bibr" rid="B174">174</xref>&#x2013;<xref ref-type="bibr" rid="B177">177</xref>].</p>
<p>In a number of other progressive neurodegenerative disorders there is increased breakdown of &#x3b1;SpII [<xref ref-type="bibr" rid="B132">132</xref>, <xref ref-type="bibr" rid="B135">135</xref>, <xref ref-type="bibr" rid="B140">140</xref>, <xref ref-type="bibr" rid="B141">141</xref>, <xref ref-type="bibr" rid="B178">178</xref>&#x2013;<xref ref-type="bibr" rid="B181">181</xref>]. It has been shown that this is due to excessive activation of calpain which results in increased cleavage of &#x3b1;SpII. Excessive activation of calpain and &#x3b1;SpII cleavage is a common feature of neurodegenerative diseases and of traumatic encephalopathy and leads to loss of neuronal integrity and the neuropathology of many of these disorders [<xref ref-type="bibr" rid="B132">132</xref>, <xref ref-type="bibr" rid="B135">135</xref>, <xref ref-type="bibr" rid="B140">140</xref>, <xref ref-type="bibr" rid="B141">141</xref>, <xref ref-type="bibr" rid="B178">178</xref>, <xref ref-type="bibr" rid="B179">179</xref>]. In Alzheimer&#x2019;s disease, increased breakdown of &#x3b1;SpII has been demonstrated in numerous cells and tissues and is due to excessive calpain activity but not to changes in levels of calpain [<xref ref-type="bibr" rid="B141">141</xref>, <xref ref-type="bibr" rid="B171">171</xref>, <xref ref-type="bibr" rid="B177">177</xref>, <xref ref-type="bibr" rid="B182">182</xref>]. It has been proposed that faulty regulation of the neuronal spectrin skeleton and its breakdown by excessive calpain activity can activate a series of events that leads to the ataxia and neuronal degeneration observed in this and other neurodegenerative disorders [<xref ref-type="bibr" rid="B135">135</xref>]. Thus, excessive activation of calpain activity in a number of neurodegenerative diseases results in loss of &#x3b1;SpII [<xref ref-type="bibr" rid="B132">132</xref>, <xref ref-type="bibr" rid="B135">135</xref>, <xref ref-type="bibr" rid="B140">140</xref>&#x2013;<xref ref-type="bibr" rid="B142">142</xref>].</p>
<p>Central nervous system and various neurological anomalies are also a clinical characteristic of FA patients. These include: brain and spinal cord anomalies, microcephaly, hydrocephalus, cerebellar defects, and development of medulloblastoma [<xref ref-type="bibr" rid="B67">67</xref>, <xref ref-type="bibr" rid="B168">168</xref>, <xref ref-type="bibr" rid="B173">173</xref>, <xref ref-type="bibr" rid="B183">183</xref>&#x2013;<xref ref-type="bibr" rid="B186">186</xref>]. Of considerable interest, FA cells have significantly (3-4 fold) increased levels of breakdown of &#x3b1;SpII due to an excessive increase in &#xb5;-calpain activity [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B69">69</xref>]. FA thus represents another disorder in which loss of &#x3b1;SpII is due to its cleavage by &#xb5;-calpain. It can be hypothesized that like some neurodegenerative diseases, excessive activation of &#x3bc;-calpain activity in FA, leading to significant cleavage of &#x3b1;SpII, may be an important contributing factor in the pathological changes observed in the nervous system and in the pathogenesis of FA. It would be of interest to determine whether there is increased &#x3bc;-calpain activity and &#x3b1;SpII cleavage in neuronal tissue in FA patients with neurological abnormalities and to speculate that, if a relationship between these two factors were found, this would indicate that breakdown of &#x3b1;SpII is an important factor in progression of these abnormalities.</p>
<p>There is evidence that a deficiency in &#x3b1;SpII plays an important role in development of cancers other than AML. In Lynch Syndrome or hereditary nonpolyposis colorectal cancer, where there is a defect in DNA mismatch repair and a deficiency in the mismatch repair protein, MLH1, there is a significant reduction in levels of &#x3b1;SpII in the tumor cells [<xref ref-type="bibr" rid="B187">187</xref>&#x2013;<xref ref-type="bibr" rid="B189">189</xref>]. Since MLH1 directly interacts with &#x3b1;SpII, it has been proposed that loss of MLH1 leads to destabilization of &#x3b1;SpII which, in turn, results in a defect in DNA repair and in the tumor development seen in this disorder [<xref ref-type="bibr" rid="B187">187</xref>&#x2013;<xref ref-type="bibr" rid="B189">189</xref>]. These studies, along with those noted above, which suggest that &#x3b1;SpII loss is an important factor in lymphomagenesis, collectively indicate that there is strong evidence that a deficiency in &#x3b1;SpII plays an important role in development of a number of different types of cancer.</p>
<p>In both acquired and neonatal congenital heart failure, there is dysfunction of &#x3b1;SpII that is due to excessive calpain activity which results in increased cleavage of &#x3b1;SpII [<xref ref-type="bibr" rid="B190">190</xref>, <xref ref-type="bibr" rid="B191">191</xref>]. This has been demonstrated by the presence of the 150&#xa0;kDa &#x3b1;SpII breakdown product of &#x3bc;-calpain in the cardiac cells [<xref ref-type="bibr" rid="B190">190</xref>, <xref ref-type="bibr" rid="B191">191</xref>]. &#x3b1;SpII is required for normal cardiac structure, function and development and plays a central role in the formation and regulation of key structural and signaling pathways in the heart [<xref ref-type="bibr" rid="B190">190</xref>, <xref ref-type="bibr" rid="B191">191</xref>]. Breakdown of &#x3b1;SpII, which can occur in heart disease, has a significant effect on the cardiomyocyte spectrin network and on regulation of normal cardiac function [<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B190">190</xref>, <xref ref-type="bibr" rid="B191">191</xref>]. Thus, breakdown of &#x3b1;SpII by excessive &#x3bc;-calpain activity is also an important factor in heart failure.</p>
<p>&#x3b1;SpII dysfunction can therefore lead to a variety of disorders, particularly since it is a multifunctional protein which is critical for a multitude of diverse cellular processes. As mentioned above, there is a relationship between clinical manifestations of all of the disorders described and a loss or deficiency in &#x3b1;SpII, which in turn is due to either enhanced cleavage of &#x3b1;SpII by excessive proteolytic cleavage by &#x3bc;-calpain or expression of a defective &#x3b1;SpII due to a mutation in the <italic>SPTAN1</italic> gene. As a result of the diversity of &#x3b1;SpII function, a deficiency in &#x3b1;SpII can lead either directly or indirectly to dysregulation of a number of different cellular pathways and to pathological changes which are manifested in a variety of different disorders. The number of disorders in which deficiencies in &#x3b1;SpII play a direct or indirect role may still not yet be fully recognized.</p>
</sec>
<sec id="s13">
<title>Conclusions and perspective</title>
<p>&#x3b1;SpII is a critically important and functionally diverse protein which represents 2&#x2013;3% of all proteins in human cells [<xref ref-type="bibr" rid="B14">14</xref>&#x2013;<xref ref-type="bibr" rid="B17">17</xref>]. It forms a network under the plasma membrane and within the cytoplasm ensuring the stability of cell membranes and organelles. It acts as a scaffold interacting with different protein binding partners playing an important role in cell development, cell migration, cell cycle, actin filament organization, intracellular trafficking and signal transduction [<xref ref-type="bibr" rid="B24">24</xref>&#x2013;<xref ref-type="bibr" rid="B28">28</xref>]. Within the nucleus, &#x3b1;SpII is part of a nucleoskeletal network which is essential for maintaining the structural integrity of the nuclear envelope and elasticity of the nucleus. It is involved in the biomechanical coupling of the nucleoskeleton to the cytoskeleton. Of particular significance, &#x3b1;SpII plays a critical role in DNA repair where it acts as a scaffold recruiting repair proteins to sites of damage, enabling DNA repair to take place [<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B50">50</xref>].</p>
<p>&#x3b1;SpII&#x2019;s stability within the cell is critical for all of its functions. It is sensitive to cleavage by the protease, &#x3bc;-calpain, and excessive activation of &#x3bc;-calpain activity leads to increased cleavage of &#x3b1;SpII and loss of its ability to function in essential cellular processes, which is a contributing factor in a number of disorders [<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B50">50</xref>]. Maintaining a balance between activation of &#x3bc;-calpain and regulation of spectrin cleavage is thus extremely important. This is particularly critical during the repair of DNA interstrand crosslinks (ICLs), where &#x3b1;SpII plays a critical role in repair of damaged sites, on both telomeric and non-telomeric DNA [<xref ref-type="bibr" rid="B46">46</xref>]. Excessive activation of &#xb5;-calpain activity leads to cleavage and breakdown of &#x3b1;SpII and loss of its ability to function in DNA repair as well as in cellular systems critical for both the structural and non-structural components of cell function [<xref ref-type="bibr" rid="B69">69</xref>]. This, in turn, leads to development of the pathological changes observed in numerous disorders.</p>
<p>One disorder in which there is a deficiency in &#x3b1;SpII is the bone marrow failure disorder, Fanconi anemia (FA), a distinctive hallmark of which is a defect in ability to repair DNA ICLs. &#x3b1;SpII levels in FA cells are 35%&#x2013;40% of normal and levels of repair are 35&#x2013;45% of normal [<xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B54">54</xref>]. Of particular significance, loss of &#x3b1;SpII in FA cells is due to increased &#xb5;-calpain activity, which is 3-4 fold greater than in normal cells, as observed in FA-A, FA-C, FA-D2, FA-F and FA-G cells [<xref ref-type="bibr" rid="B69">69</xref>]. This leads to increased cleavage of &#x3b1;SpII and decreased DNA ICL repair capabilities in both telomeric and non-telomeric DNA (<xref ref-type="fig" rid="F11">Figure 11A</xref>). However, when levels of &#xb5;-calpain are knocked down, there is decreased cleavage of &#x3b1;SpII, whose levels return to those found in normal cells, and restoration of DNA ICL repair in these cells (<xref ref-type="fig" rid="F11">Figure 11B</xref>). Another characteristic hallmark of FA is chromosome instability. After DNA ICL damage, a number of chromosomal aberrations occur in FA cells such as sister chromatid end-to-end fusions, chromatin breaks, chromosome exchanges and radials [<xref ref-type="bibr" rid="B45">45</xref>]. In FA cells in which &#xb5;-calpain has been knocked down, &#x3b1;SpII stability is restored leading to restoration of chromosomal stability and a decrease in chromosome aberrations after DNA ICL damage. This indicates that &#x3b1;SpII plays an important role in both DNA repair and chromosome stability after DNA ICL damage.</p>
<fig id="F11" position="float">
<label>FIGURE 11</label>
<caption>
<p>Role of &#xb5;-calpain in the deficiency of &#x3b1;SpII in FA cells and in defective DNA ICL repair in these cells. FA-A cells are used as a model. <bold>(A)</bold> In FA-A cells, excessive &#xb5;-calpain activity, decreased levels of individual FA proteins and increased accessibility of &#x3b1;SpII to &#xb5;-calpain lead to increased cleavage of &#x3b1;SpII by &#xb5;-calpain. FA-A cells, transfected with a non-target siRNA and examined using indirect immunofluorescence and staining with anti-&#x3b1;SpII, show low levels of &#x3b1;SpII and few nuclear foci after MMC treatment. Staining of the cells with anti-XPF shows that XPF is present in these cells but, after MMC treatment, few XPF foci are seen. <bold>(B)</bold> In FA-A cells, in which &#xb5;-calpain has been knocked down by &#xb5;-calpain siRNA, there is decreased cleavage of &#x3b1;SpII. Examination of these cells using immunofluorescence shows that &#x3b1;SpII is present in the nucleus and forms foci after treatment with MMC. XPF also forms nuclear foci in these cells after MMC treatment.</p>
</caption>
<graphic xlink:href="ebm-250-10537-g011.tif"/>
</fig>
<p>Lambert et al. have hypothesized that excessive cleavage of &#x3b1;SpII in FA cells is an important contributing factor in the pathogenesis of this disorder [<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B50">50</xref>]. The strongest evidence supporting this is from the studies noted above on the critical role of &#x3b1;SpII in DNA repair and in chromosome stability, since defects in these two processes are of major importance in FA pathogenesis. &#x3b1;SpII has been shown to play a direct role in DNA ICL repair and in the repair defect in FA. It binds directly to DNA containing ICLS and its involvement in the repair process has been demonstrated both by measurement of unscheduled DNA synthesis (UDS) after damage, which measures uptake of nucleotides into DNA repair patches, and by localization of the repair protein, XPF, to sites of DNA ICLs in normal and FA cells [<xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B47">47</xref>]. These studies indicate that breakdown of &#x3b1;SpII in FA cells is directly related to the defect in DNA ICL repair. An important question is what are the factors that are important in maintaining the stability of &#x3b1;SpII in FA cells. Studies have demonstrated that one of these is regulation of cleavage of &#x3b1;SpII by &#x3bc;-calpain.</p>
<p>Excessive cleavage of &#x3b1;SpII by &#xb5;-calpain and its involvement in the DNA repair defect in FA cells has been demonstrated both by the presence of the 150&#xa0;Kd &#x3b1;SpII breakdown product of &#xb5;-calpain in FA cells and by studies which show that knocking down &#x3bc;-calpain corrects the excessive cleavage of &#x3b1;SpII and the DNA repair defect [<xref ref-type="bibr" rid="B69">69</xref>]. This needs to be examined in more FA complementation groups. It will also be important to determine whether there are other proteins involved in &#x3b1;SpII cleavage. Calmodulin, for example, binds to a site on &#x3b1;SpII and can stimulate &#xb5;-calpain activity. Studies need to be carried out to determine whether increased binding of calmodulin to &#x3b1;SpII in FA cells plays a role in the increased &#xb5;-calpain activity observed and the increased breakdown of &#x3b1;SpII.</p>
<p>FA proteins are known to play a role in the DNA ICL repair pathway. Lambert et al. have hypothesized that they also play an important role, either directly or indirectly, in maintaining &#x3b1;SpII stability. Transfection of FA cells (FA-A, FA-C, and FA-G) with the corresponding FANC-cDNA, which results in expression of either FANCA, FANCC or FANCG, respectively, restores &#x3b1;SpII stability and leads to restoration of chromosomal stability [<xref ref-type="bibr" rid="B69">69</xref>]. FANCG has been shown to directly bind to the SH3 domain in &#x3b1;SpII [<xref ref-type="bibr" rid="B101">101</xref>]. It has been proposed that FANCG may be involved in aiding in maintenance of &#x3b1;SpII stability by directly preventing binding of low molecular weight phosphotyrosine phosphatase (LMW-PTP) to its SH3 domain, which would lead to dephosphorylation of residue Y1176 at &#x3bc;-calpain&#x2019;s cleavage site adjacent to the SH3 domain (<xref ref-type="fig" rid="F1">Figure 1</xref>) and allow &#xb5;calpain to cleave &#x3b1;SpII at this site [<xref ref-type="bibr" rid="B101">101</xref>]. Binding of FANCG to the SH3 domain would aid in preventing cleavage of &#x3b1;SpII by &#x3bc;-calpain. This needs to be further investigated. Other FA proteins could also interact with &#x3b1;SpII to protect it from cleavage by &#xb5;-calpain or bind to &#xb5;-calpain or calmodulin and prevent their activity, either directly or indirectly, via other proteins. FANCA and FANCG, for example, have been shown to bind directly to &#x3bc;calpain [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B50">50</xref>]. Whether this binding can decrease the activity of &#xb5;-calpain and enhance &#x3b1;SpII stability needs to be examined. Similarly, binding of a FA protein to calmodulin could inhibit its ability to bind to &#x3bc;-calpain and activate it, which would also enhance &#x3b1;SpII stability. Thus, binding of FA proteins to &#x3b1;SpII or to associated proteins such as &#x3bc;calpain or calmodulin could have an important effect on &#x3b1;SpII stability, protecting it from cleavage by &#xb5;-calpain. Studies need to be carried out on all of these possibilities.</p>
<p>Numerous studies have been done on the direct role FA proteins play in repair of DNA ICLs. In one of these, knockdown of the <italic>FANCA</italic> and <italic>FANCD2</italic> genes in human embryonic stem cells was shown to lead to a marked reduction in localization of FANCA and FANCD2 proteins to ICL damage induced foci, indicating presence of a defect in DNA ICL repair [<xref ref-type="bibr" rid="B192">192</xref>]. Chromosomal aberrations such as breaks and radials also formed [<xref ref-type="bibr" rid="B192">192</xref>]. It would be interesting to determine, in studies such as these, whether a decrease in FANCA or FANCD2 proteins leads not only to direct effects on DNA ILC repair but also to loss of stability and breakdown of &#x3b1;SpII. If this occurred, it would suggest that loss of the FA protein led to increased breakdown of &#x3b1;SpII and to the increased defect in DNA repair and chromosome stability observed after DNA ICL damage. These studies would also emphasize the importance of FA proteins in aiding in maintenance of the stability of &#x3b1;SpII in cells, as has been suggested.</p>
<p>Another distinctive hallmark of FA is chromosome instability. The importance of &#x3b1;SpII in maintenance of chromosome stability is seen in studies in which knock down of &#x3b1;SpII in normal cells leads to production of chromosomal aberrations [<xref ref-type="bibr" rid="B45">45</xref>]. In addition, in FA cells when levels of &#x3b1;SpII are returned to normal by knocking down &#x3bc;-calpain, chromosome stability is restored indicating that &#x3b1;SpII plays a role in this process [<xref ref-type="bibr" rid="B45">45</xref>]. The effect that excessive cleavage of &#x3b1;SpII in FA cells has on chromosome stability could be directly related to the defect in the ICL repair process and the increase in un-repaired DNA which is produced in these cells. It has been shown that un-repaired or misrepaired lesions in DNA can lead to chromosomal aberrations [<xref ref-type="bibr" rid="B164">164</xref>]. Cells are particularly sensitive to un-repaired DNA ICLS, which can lead to DNA double-strand break formation in S phase of the cell cycle and to chromosomal aberrations [<xref ref-type="bibr" rid="B164">164</xref>]. In FA cells, breakdown of &#x3b1;SpII could thus be important in production of the chromosomal aberrations observed, which particularly occur after DNA ICL damage and which are not effectively repaired in these cells.</p>
<p>Lambert et al. have also hypothesized that excessive cleavage of &#x3b1;SpII in FA cells may be an important contributing factor in some of the other characteristics of FA pathogenesis such as bone marrow failure, development of AML, congenital anomalies and neurological abnormalities [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B44">44</xref>]. Studies have shown, for example, that there is a loss of &#x3b1;SpII in bone marrow of patients with AML and it has been proposed that this loss may be contributing to AML development and to leukemogenesis [<xref ref-type="bibr" rid="B165">165</xref>, <xref ref-type="bibr" rid="B167">167</xref>]. It can be hypothesized that since FA patients can develop AML, a deficiency in &#x3b1;SpII is a contributing factor in its development. Excessive cleavage and loss of &#x3b1;SpII also occurs in a number of neurodegenerative disorders. This is due to excessive activation of calpain and is a common feature of the neuropathology of many of these disorders. Neurological abnormalities are also a characteristic of FA patients [<xref ref-type="bibr" rid="B67">67</xref>, <xref ref-type="bibr" rid="B168">168</xref>, <xref ref-type="bibr" rid="B183">183</xref>&#x2013;<xref ref-type="bibr" rid="B186">186</xref>]. It is possible that excessive calpain activity may thus be an important factor contributing to the loss of &#x3b1;SpII and to a number of the neurological anomalies observed in FA. FA could thus represent another disorder in which there is excessive cleavage of &#x3b1;SpII by &#x3bc;-calpain. Studies needs to be carried out on this in more complementation groups of FA. Since &#x3b1;SpII is a multifunctional protein, it is not surprising that a deficiency in it could lead to deficiencies in multiple cellular pathways and result in a number of the different pathological manifestations observed in FA.</p>
<p>This review has focused on the important role of &#x3b1;SpII in repair of DNA ICLs in telomeric and non-telomeric DNA and on the importance of maintaining the stability of &#x3b1;SpII not only for DNA repair but also for other cellular processes. Two factors which have been shown to be critical for maintaining &#x3b1;SpII stability in the cell are the levels of &#x3bc;-calpain activity and the presence of FA proteins. Excess &#x3bc;-calpain activity in FA cells has been demonstrated to lead to breakdown of &#x3b1;SpII. FA proteins are proposed to play a role in regulation of &#x3b1;SpII stability by modulating its cleavage by &#x3bc;-calpain. Direct binding of FANCG to &#x3b1;SpII has been demonstrated but the effects this binding has on &#x3b1;SpII stability and its cleavage by &#x3bc;-calpain needs to be further investigated as does the effect of other FA proteins on this process.</p>
<p>Since &#x3b1;SpII has a wide spectrum of functions in a number of different cellular and physiological processes, it is possible that in FA cells excessive cleavage of &#x3b1;SpII by &#x3bc;-calpain could have an important effect on some of the clinical characteristics of this disorder. Decreasing &#x3bc;-calpain activity in FA cells could aid in stabilization of &#x3b1;SpII and be of potential therapeutic relevance. Lambert et al. have shown that knocking down &#x3bc;calpain activity in FA cells to levels found in normal cells does not have any adverse effects on cell survival and it leads to restoration of &#x3b1;SpII to normal levels and enables DNA ICL repair to proceed. Though levels of &#x3bc;-calpain have been reduced to normal in these cells, the deficiency in the FA protein specific for the FA complementation group being examined has not been corrected. However, DNA repair takes place. FANCD2-Ub is not present but non-Ub FANCD2 is and it localizes in foci at sites of damage. &#x3b1;SpII is needed for this to occur [<xref ref-type="bibr" rid="B49">49</xref>]. &#x3b1;SpII localizes in foci at sites of damage along with XPF but not with non-Ub FANCD2. It has been proposed that this could be a backup system in which non-Ub FANCD2 is involved in the repair process [<xref ref-type="bibr" rid="B49">49</xref>]. In these FA cells, if a specific FA protein is not available to help stabilize &#x3b1;SpII, restoration of &#x3b1;SpII to normal levels by knocking down &#x3bc;-calpain could, to some extent, counteract this need for the FA protein in this process. Whether this holds true for all of the FA complementation groups needs to be examined.</p>
<p>It is hypothesized that there is a mechanistic link between excessive &#x3bc;-calpain activity, cleavage of &#x3b1;SpII, and defective DNA ICL repair, and that these are key factors in the pathogenesis of FA. FA proteins are proposed to play a role in modulating &#x3b1;SpII cleavage by &#x3bc;-calpain. Correcting the excessive cleavage of &#x3b1;SpII in FA cell is particularly important since &#x3b1;SpII is essential for a number of critical cellular and physiological processes, such as DNA repair. These studies suggest a new direction for correction of a number of the phenotypic deficiencies in FA cells. Thus, stabilization of &#x3b1;SpII in FA by reducing &#x3bc;-calpain activity, potentially in combination with other modalities, could potentially reduce the DNA repair defect and other systemic deficiencies which lead to the clinical manifestations of this as well as other disorders.</p>
</sec>
</body>
<back>
<sec sec-type="author-contributions" id="s14">
<title>Author contributions</title>
<p>ML wrote the manuscript and prepared the figures.</p>
</sec>
<sec sec-type="funding-information" id="s15">
<title>Funding</title>
<p>The author(s) declare that no financial support was received for the research and/or publication of this article.</p>
</sec>
<sec sec-type="COI-statement" id="s16">
<title>Conflict of interest</title>
<p>The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</sec>
<sec sec-type="ai-statement" id="s17">
<title>Generative AI statement</title>
<p>The authors declare that no Generative AI was used in the creation of this manuscript.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hohmann</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Dehghani</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>The cytoskeleton &#x2013; a complex interacting meshwork</article-title>. <source>Cells</source> (<year>2019</year>) <volume>8</volume>:<fpage>362</fpage>. <pub-id pub-id-type="doi">10.3390/cells8040362</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Svitkina</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>The actin cytoskeleton and actin-based motility</article-title>. <source>Cold Spring Harbor Perspect Biol</source> (<year>2018</year>) <volume>10</volume>:<fpage>a018267</fpage>. <pub-id pub-id-type="doi">10.1101/cshperspect.a018267</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Merino</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Pospich</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Raunser</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Towards a structural understanding of the remodeling of the actin cytoskeleton</article-title>. <source>Semin Cell &#x26; Developmental Biol</source> (<year>2020</year>) <volume>102</volume>:<fpage>51</fpage>&#x2013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.semcdb.2019.11.018</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Etienne-Manneville</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Cytoplasmic intermediate filaments in cell biology</article-title>. <source>Annu Rev Cell Dev Biol</source> (<year>2018</year>) <volume>34</volume>:<fpage>1</fpage>&#x2013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-cellbio-100617-062534</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benoit</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Baillet</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pous</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Cytoskeleton and associated proteins: pleiotropic JNK substrates and regulators</article-title>. <source>Int J Mol Sci</source> (<year>2021</year>) <volume>22</volume>:<fpage>8375</fpage>. <pub-id pub-id-type="doi">10.3390/ijms22168375</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dechat</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Pfleghaar</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sengupta</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Shimi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shumaker</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Solimando</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group> <article-title>Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin</article-title>. <source>Genes Dev</source> (<year>2008</year>) <volume>22</volume>:<fpage>832</fpage>&#x2013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1101/gad.1652708</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simon</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>KL</given-names>
</name>
</person-group>. <article-title>The nucleoskeleton as a genome-associated dynamic network of networks</article-title>. <source>Nat Rev Mol Cell Biol</source> (<year>2011</year>) <volume>12</volume>:<fpage>695</fpage>&#x2013;<lpage>708</lpage>. <pub-id pub-id-type="doi">10.1038/nrm3207</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldman</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Gruenbaum</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Moir</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Shumaker</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Spann</surname>
<given-names>TP</given-names>
</name>
</person-group>. <article-title>Nuclear lamins: building blocks of nuclear architecture</article-title>. <source>Genes &#x26; Development</source> (<year>2002</year>) <volume>16</volume>:<fpage>533</fpage>&#x2013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1101/gad.960502</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Dawson</surname>
<given-names>SC</given-names>
</name>
</person-group>. <article-title>Functional evolution of nuclear structure</article-title>. <source>J Cell Biol</source> (<year>2011</year>) <volume>195</volume>:<fpage>171</fpage>&#x2013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.201103171</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhong</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Dahl</surname>
<given-names>KN</given-names>
</name>
</person-group>. <article-title>Beyond lamins: other structural components of the nucleoskeleton</article-title>. <source>Methods Cell Biol</source> (<year>2010</year>) <volume>98</volume>:<fpage>97</fpage>&#x2013;<lpage>119</lpage>. <pub-id pub-id-type="doi">10.1016/s0091-679x(10)98005-9</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lammerding</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schulze</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Takahaski</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kozlov</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kamm</surname>
<given-names>RD</given-names>
</name>
<etal/>
</person-group> <article-title>Lamin A/C deficiency causes defective nuclear mechanics and mechanotransduction</article-title>. <source>J Clin Invest</source> (<year>2004</year>) <volume>113</volume>:<fpage>370</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1172/jc119670</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McMahon</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Walsh</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>MW</given-names>
</name>
</person-group>. <article-title>Human &#x3b1; spectrin II and the Fanconi anemia proteins FANCA and FANCC interact to form a nuclear complex</article-title>. <source>J Biol Chem</source> (<year>1999</year>) <volume>274</volume>:<fpage>32904</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.274.46.32904</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lambert</surname>
<given-names>MW</given-names>
</name>
</person-group>. <article-title>Spectrin and its interacting partners in nuclear structure and function</article-title>. <source>Exp Biol Med</source> (<year>2018</year>) <volume>243</volume>:<fpage>507</fpage>&#x2013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1177/1535370218763563</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodman</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Youngentob</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Kakhniashvili</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>The spectrinome: the interactome of a scaffold protein creating nuclear and cytoplasmic connectivity and function</article-title>. <source>Exp Biol Med</source> (<year>2019</year>) <volume>244</volume>:<fpage>1273</fpage>&#x2013;<lpage>302</lpage>. <pub-id pub-id-type="doi">10.1177/1535370219867269</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Winkelmann</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Forget</surname>
<given-names>BG</given-names>
</name>
</person-group>. <article-title>Erythroid and nonerythroid spectrins</article-title>. <source>Blood</source> (<year>1993</year>) <volume>81</volume>:<fpage>3173</fpage>&#x2013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1182/blood.v81.12.3173.bloodjournal81123173</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodman</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Zimmer</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Zagon</surname>
<given-names>IS</given-names>
</name>
<name>
<surname>Barker</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Bloom</surname>
<given-names>ML</given-names>
</name>
</person-group>. <article-title>Brain spectrin: of mice and men</article-title>. <source>Brain Res Bull</source> (<year>1995</year>) <volume>36</volume>:<fpage>593</fpage>&#x2013;<lpage>606</lpage>. <pub-id pub-id-type="doi">10.1016/0361-9230(94)00264-2</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Matteis</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Morrow</surname>
<given-names>JS</given-names>
</name>
</person-group>. <article-title>Spectrin tethers and mesh in the biosynthetic pathway</article-title>. <source>J Cell Sci</source> (<year>2000</year>) <volume>113</volume>:<fpage>2331</fpage>&#x2013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.113.13.2331</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marchesi</surname>
<given-names>VT</given-names>
</name>
<name>
<surname>Steers</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Selective solubilization of a protein component of the red cell membrane</article-title>. <source>Science</source> (<year>1968</year>) <volume>159</volume>:<fpage>203</fpage>&#x2013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1126/science.159.3811.203</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodman</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Zagon</surname>
<given-names>IS</given-names>
</name>
<name>
<surname>Kulikowski</surname>
<given-names>RR</given-names>
</name>
</person-group>. <article-title>Identification of a spectrin-like protein in nonerythroid cells</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>1981</year>) <volume>78</volume>:<fpage>7570</fpage>&#x2013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.78.12.7570</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodman</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Shiffer</surname>
<given-names>KA</given-names>
</name>
</person-group>. <article-title>The spectrin membrane skeleton of normal and abnormal human erythrocytes: a review</article-title>. <source>Am J Physiology-Cell Physiol</source> (<year>1983</year>) <volume>244</volume>:<fpage>C121</fpage>&#x2013;<lpage>C141</lpage>. <pub-id pub-id-type="doi">10.1152/ajpcell.1983.244.3.c121</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Bullitt</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sriswasdi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Harper</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Speicher</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>McKnight</surname>
<given-names>CJ</given-names>
</name>
</person-group>. <article-title>The physiological molecular shape of spectrin: a compact supercoil resembling a Chinese finger trap</article-title>. <source>PLOS Comput Biol</source> (<year>2015</year>) <volume>11</volume>:<fpage>e1004302</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pcbi.1004302</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodman</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Kurdia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ammann</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kakhniashvili</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Daescu</surname>
<given-names>O</given-names>
</name>
</person-group>. <article-title>The human red blood cell proteome and interactome</article-title>. <source>Exp Biol Med</source> (<year>2007</year>) <volume>232</volume>:<fpage>1391</fpage>&#x2013;<lpage>408</lpage>. <pub-id pub-id-type="doi">10.3181/0706-mr-156</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodman</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Daescu</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Kakhniashvili</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zivanic</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>The proteomics and interactomics of human erythrocytes</article-title>. <source>Exp Biol Med</source> (<year>2013</year>) <volume>238</volume>:<fpage>509</fpage>&#x2013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1177/1535370213488474</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Machnicka</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Czogalla</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hryniewicz-Jankowska</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bogus&#x142;awska</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Grochowalska</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Heger</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group> <article-title>Spectrins: a structural platform for stabilization and activation of membrane channels, receptors and transporters</article-title>. <source>Biochim Biophys Acta (Bba) - Biomembranes</source> (<year>2014</year>) <volume>1838</volume>:<fpage>620</fpage>&#x2013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamem.2013.05.002</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bennet</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Baines</surname>
<given-names>AJ</given-names>
</name>
</person-group>. <article-title>Spectrin and ankyrin-based pathways: metazoan inventions for integrating cells into tissues</article-title>. <source>Physiol Rev</source> (<year>2001</year>) <volume>81</volume>:<fpage>353</fpage>&#x2013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.2001.81.3.1353</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodman</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Chapa</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Zimmer</surname>
<given-names>WE</given-names>
</name>
</person-group>. <article-title>Spectrin&#x2019;s chimeric E2/E3 enzymatic activity</article-title>. <source>Exptl Biol Med</source> (<year>2015</year>) <volume>240</volume>:<fpage>1039</fpage>&#x2013;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1177/1535370215596084</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Machnicka</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Grochowalska</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bogus&#x142;awska</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Sikorski</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Lecomte</surname>
<given-names>MC</given-names>
</name>
</person-group>. <article-title>Spectrin-based skeleton as an actor in cell signaling</article-title>. <source>Cell Mol Life Sci</source> (<year>2012</year>) <volume>69</volume>:<fpage>191</fpage>&#x2013;<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-011-0804-5</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sikorski</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sangerman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Goodman</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Critz</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Spectrin (&#x3b2;SpII&#x3a3;1) is an essential component of synaptic transmission</article-title>. <source>Brain Res</source> (<year>2000</year>) <volume>852</volume>:<fpage>161</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/s0006-8993(99)02253-2</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodman</surname>
<given-names>SR</given-names>
</name>
</person-group>. <article-title>Discovery of nonerythroid spectrin to the demonstration of its key role in synaptic transmission</article-title>. <source>Brain Res Bull</source> (<year>1999</year>) <volume>50</volume>:<fpage>345</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/s0361-9230(99)00098-2</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ponceau</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Albiges-Rizo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Colin-Aronovicz</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Destaing</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Lecomte</surname>
<given-names>MC</given-names>
</name>
</person-group>. <article-title>&#x3b1;IISpectrin regulates invadosome stability and extracellular matrix degradation</article-title>. <source>PLoS ONE</source> (<year>2015</year>) <volume>10</volume>:<fpage>e0120781</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0120781</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trinh-Trang-Tan</surname>
<given-names>M-M</given-names>
</name>
<name>
<surname>Bigot</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Picot</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lecomte</surname>
<given-names>M-C</given-names>
</name>
<name>
<surname>Kordeli</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>AlphaII-spectrin participates in the surface expression of cell adhesion molecule L1 and neurite outgrowth</article-title>. <source>Exp Cell Res</source> (<year>2014</year>) <volume>322</volume>:<fpage>365</fpage>&#x2013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.yexcr.2014.01.012</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meissner</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Sikorski</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Nawara</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Grzesiak</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Marycz</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bogus&#x142;awska</surname>
<given-names>DM</given-names>
</name>
<etal/>
</person-group> <article-title>&#x3b1;II-spectrin in T cells is involved in the regulation of cell-cell contact leading to immunological synapse formation?</article-title> <source>PLOS ONE</source> (<year>2017</year>) <volume>12</volume>:<fpage>e0189545</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0189545</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Metral</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Machnicka</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bigot</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Colin</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Dhermy</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lecomte</surname>
<given-names>M-C</given-names>
</name>
</person-group>. <article-title>&#x3b1;II-spectrin is critical for cell adhesion and cell cycle</article-title>. <source>J Biol Chem</source> (<year>2009</year>) <volume>284</volume>:<fpage>2409</fpage>&#x2013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.m801324200</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zagon</surname>
<given-names>IS</given-names>
</name>
<name>
<surname>Higbee</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Riederer</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Goodman</surname>
<given-names>SR</given-names>
</name>
</person-group>. <article-title>Spectrin subtypes in mammalian brain: an immunoelectron microscopic study</article-title>. <source>J Neurosci</source> (<year>1986</year>) <volume>6</volume>:<fpage>2977</fpage>&#x2013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.06-10-02977.1986</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gascard</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mohandas</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>New insights into functions of erythroid proteins in nonerythroid cells</article-title>. <source>Curr Opin Hematol</source> (<year>2000</year>) <volume>7</volume>:<fpage>123</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/00062752-200003000-00009</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stankewich</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Cianci</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Stabach</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Nath</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Morrow</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Cell organization, growth, and neural and cardiac development require &#x3b1;II-spectrin</article-title>. <source>J Cell Sci</source> (<year>2011</year>) <volume>124</volume>:<fpage>3956</fpage>&#x2013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.080374</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Armiger</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Spagnol</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Dahl</surname>
<given-names>KN</given-names>
</name>
</person-group>. <article-title>Nuclear mechanical resilience but not stiffness is modulated by &#x3b1;II-spectrin</article-title>. <source>J Biomech</source> (<year>2016</year>) <volume>49</volume>:<fpage>3983</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.jbiomech.2016.10.034</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lambert</surname>
<given-names>MW</given-names>
</name>
</person-group>. <article-title>Functional significance of nuclear &#x3b1; spectrin</article-title>. <source>J Cell Biochem</source> (<year>2015</year>) <volume>116</volume>:<fpage>1816</fpage>&#x2013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.25123</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tse</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Korsgren</surname>
<given-names>C</given-names>
</name>
<name>
<surname>John</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Kung</surname>
<given-names>AL</given-names>
</name>
<etal/>
</person-group> <article-title>A new spectrin, beta IV, has a major truncated isoform that associates with promyelocytic leukemia protein nuclear bodies and the nuclear matrix</article-title>. <source>J Biol Chem</source> (<year>2001</year>) <volume>276</volume>:<fpage>23974</fpage>&#x2013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.m009307200</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thenappan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shukkla</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Abdul Khalek</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shetty</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group> <article-title>Loss of TGF&#x3b2; adaptor protein &#x3b2;2SP leads to delayed liver regeneration in mice</article-title>. <source>Hepatology</source> (<year>2011</year>) <volume>53</volume>:<fpage>1641</fpage>&#x2013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1002/hep.24111</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sridharan</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>MW</given-names>
</name>
</person-group>. <article-title>&#x3b1;II-Spectrin interacts with five groups of functionally important proteins in the nucleus</article-title>. <source>Cell Biol Int</source> (<year>2006</year>) <volume>30</volume>:<fpage>866</fpage>&#x2013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1016/j.cellbi.2006.06.005</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McMahon</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Sangerman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Goodman</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Kumaresan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>MW</given-names>
</name>
</person-group>. <article-title>Human alpha spectrin II and the FANCA, FANCC, and FANCG proteins bind to DNA containing psoralen interstrand cross-links</article-title>. <source>Biochemistry</source> (<year>2001</year>) <volume>40</volume>:<fpage>7025</fpage>&#x2013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1021/bi002917g</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sridharan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>MW</given-names>
</name>
</person-group>. <article-title>Nonerythroid alpha II spectrin is required for recruitment of FANCA and XPF to nuclear foci induced by DNA interstrand cross-links</article-title>. <source>J Cell Sci</source> (<year>2003</year>) <volume>116</volume>:<fpage>823</fpage>&#x2013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.00294</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lambert</surname>
<given-names>MW</given-names>
</name>
</person-group>. <article-title>Nuclear alpha spectrin: critical roles in DNA interstrand cross-link repair and genomic stability</article-title>. <source>Exp Biol Med</source> (<year>2016</year>) <volume>241</volume>:<fpage>1621</fpage>&#x2013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1177/1535370216662714</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McMahon</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sridharan</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Lefferts</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>MW</given-names>
</name>
</person-group>. <article-title>Knockdown of &#x3b1;II spectrin in normal human cells by siRNA leads to chromosomal instability and decreased DNA interstrand cross-link repair</article-title>. <source>Biochem Biophysical Res Commun</source> (<year>2009</year>) <volume>381</volume>:<fpage>288</fpage>&#x2013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2009.02.038</pub-id>
</citation>
</ref>
<ref id="B46">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Herbig</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Coffman</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>MW</given-names>
</name>
</person-group>. <article-title>Non-erythroid alpha spectrin prevents telomere dysfunction after DNA interstrand cross-link damage</article-title>. <source>Nucleic Acids Res</source> (<year>2013</year>) <volume>41</volume>:<fpage>5321</fpage>&#x2013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkt235</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumaresan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sridharan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>MW</given-names>
</name>
</person-group>. <article-title>Deficiency in incisions produced by XPF at the site of a DNA interstrand cross-link in Fanconi anemia cells</article-title>. <source>Biochemistry</source> (<year>2007</year>) <volume>46</volume>:<fpage>14359</fpage>&#x2013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1021/bi7015958</pub-id>
</citation>
</ref>
<ref id="B48">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brois</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Ramos</surname>
<given-names>NI</given-names>
</name>
<name>
<surname>Anglin</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Walsh</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>MW</given-names>
</name>
</person-group>. <article-title>A deficiency in a 230 kDa DNA repair protein in Fanconi anemia complementation group A cells is corrected by the FANCA cDNA</article-title>. <source>Carcinogenesis</source> (<year>1999</year>) <volume>20</volume>:<fpage>1845</fpage>&#x2013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1093/carcin/20.9.1845</pub-id>
</citation>
</ref>
<ref id="B49">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sridharan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>MW</given-names>
</name>
</person-group>. <article-title>Nuclear &#x3b1; spectrin differentially affects monoubiquitinated versus non-ubiquitinated FANCD2 function after DNA interstrand cross-link damage</article-title>. <source>J Cell Biochem</source> (<year>2016</year>) <volume>117</volume>:<fpage>671</fpage>&#x2013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.25352</pub-id>
</citation>
</ref>
<ref id="B50">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lambert</surname>
<given-names>MW</given-names>
</name>
</person-group>. <article-title>The functional importance of lamins, actin, myosin, spectrin and the LINC complex in DNA repair</article-title>. <source>Exp Biol Med</source> (<year>2019</year>) <volume>244</volume>:<fpage>1382</fpage>&#x2013;<lpage>406</lpage>. <pub-id pub-id-type="doi">10.1177/1535370219876651</pub-id>
</citation>
</ref>
<ref id="B51">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mathew</surname>
<given-names>CG</given-names>
</name>
</person-group>. <article-title>Fanconi anaemia genes and susceptibility to cancer</article-title>. <source>Oncogene</source> (<year>2006</year>) <volume>25</volume>:<fpage>5875</fpage>&#x2013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1209878</pub-id>
</citation>
</ref>
<ref id="B52">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Winter</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Joenje</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>The genetic and molecular basis of Fanconi anemia</article-title>. <source>Mutat Research/Fundamental Mol Mech Mutagenesis</source> (<year>2009</year>) <volume>668</volume>:<fpage>11</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.mrfmmm.2008.11.004</pub-id>
</citation>
</ref>
<ref id="B53">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moldovan</surname>
<given-names>G-L</given-names>
</name>
<name>
<surname>D&#x2019;Andrea</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>How the Fanconi anemia pathway guards the genome</article-title>. <source>Annu Rev Genet</source> (<year>2009</year>) <volume>43</volume>:<fpage>223</fpage>&#x2013;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-genet-102108-134222</pub-id>
</citation>
</ref>
<ref id="B54">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumaresan</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>MW</given-names>
</name>
</person-group>. <article-title>Fanconi anemia, complementation group A, cells are defective in ability to produce incisions at sites of psoralen interstrand cross-links</article-title>. <source>Carcinogenesis</source> (<year>2000</year>) <volume>21</volume>:<fpage>741</fpage>&#x2013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1093/carcin/21.4.741</pub-id>
</citation>
</ref>
<ref id="B55">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lambert</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Tsongalis</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Parrish</surname>
<given-names>DD</given-names>
</name>
</person-group>. <article-title>Correction of the DNA repair defect in Fanconi anemia complementation groups A and D cells</article-title>. <source>Biochem Biophysical Res Commun</source> (<year>1997</year>) <volume>230</volume>:<fpage>587</fpage>&#x2013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1006/bbrc.1996.6008</pub-id>
</citation>
</ref>
<ref id="B56">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brosh</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Bellani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Seidman</surname>
<given-names>MM</given-names>
</name>
</person-group>. <article-title>Fanconi anemia: a DNA repair disorder characterized by accelerated decline of the hematopoietic stem cell compartment and other features of aging</article-title>. <source>Ageing Res Rev</source> (<year>2017</year>) <volume>33</volume>:<fpage>67</fpage>&#x2013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1016/j.arr.2016.05.005</pub-id>
</citation>
</ref>
<ref id="B57">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niraj</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Farkkila</surname>
<given-names>A</given-names>
</name>
<name>
<surname>D&#x2019;Andrea</surname>
<given-names>AD</given-names>
</name>
</person-group>. <article-title>The Fanconi anemia pathway in cancer</article-title>. <source>Annu Rev Cancer Biol</source> (<year>2019</year>) <volume>3</volume>:<fpage>457</fpage>&#x2013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-cancerbio-030617-050422</pub-id>
</citation>
</ref>
<ref id="B58">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>H</given-names>
</name>
<name>
<surname>D&#x2019;Andrea</surname>
<given-names>AD</given-names>
</name>
</person-group>. <article-title>Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway</article-title>. <source>Genes &#x26; Development</source> (<year>2012</year>) <volume>26</volume>:<fpage>1393</fpage>&#x2013;<lpage>408</lpage>. <pub-id pub-id-type="doi">10.1101/gad.195248.112</pub-id>
</citation>
</ref>
<ref id="B59">
<label>59.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kottemann</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Smogorzewska</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Fanconi anaemia and the repair of Watson and Crick DNA crosslinks</article-title>. <source>Nature</source> (<year>2013</year>) <volume>493</volume>:<fpage>356</fpage>&#x2013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1038/nature11863</pub-id>
</citation>
</ref>
<ref id="B60">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mamrak</surname>
<given-names>NE</given-names>
</name>
<name>
<surname>Shimamura</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Howlett</surname>
<given-names>NG</given-names>
</name>
</person-group>. <article-title>Recent discoveries in the molecular pathogenesis of the inherited bone marrow failure syndrome Fanconi anemia</article-title>. <source>Blood Rev</source> (<year>2017</year>) <volume>31</volume>:<fpage>93</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.blre.2016.10.002</pub-id>
</citation>
</ref>
<ref id="B61">
<label>61.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheung</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Taniguchi</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Recent insights into the molecular basis of Fanconi anemia: genes, modifiers, and drivers</article-title>. <source>Int J Hematol</source> (<year>2017</year>) <volume>106</volume>:<fpage>335</fpage>&#x2013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1007/s12185-017-2283-4</pub-id>
</citation>
</ref>
<ref id="B62">
<label>62.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosenberg</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Alter</surname>
<given-names>BP</given-names>
</name>
</person-group>. <article-title>Cancer incidence in persons with Fanconi anemia</article-title>. <source>Blood</source> (<year>2003</year>) <volume>101</volume>:<fpage>822</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2002-05-1498</pub-id>
</citation>
</ref>
<ref id="B63">
<label>63.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swuec</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ranault</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Borg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>VJ</given-names>
</name>
<name>
<surname>van Twest</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>The FA core complex contains a homo-dimeric catalytic module for symmetric mono-ubiquitination of FANCI-FANCD2</article-title>. <source>Cell Rep</source> (<year>2017</year>) <volume>18</volume>:<fpage>611</fpage>&#x2013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2016.11.013</pub-id>
</citation>
</ref>
<ref id="B64">
<label>64.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nalepa</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Clapp</surname>
<given-names>DW</given-names>
</name>
</person-group>. <article-title>Fanconi anaemia and cancer: an intricate relationship</article-title>. <source>Nat Rev Cancer</source> (<year>2018</year>) <volume>18</volume>:<fpage>168</fpage>&#x2013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1038/nrc.2017.116</pub-id>
</citation>
</ref>
<ref id="B65">
<label>65.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garaycoechea</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>KJ</given-names>
</name>
</person-group>. <article-title>Why does the bone marrow fail in Fanconi anemia?</article-title> <source>Blood</source> (<year>2014</year>) <volume>123</volume>:<fpage>26</fpage>&#x2013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2013-09-427740</pub-id>
</citation>
</ref>
<ref id="B66">
<label>66.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rageul</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Fanconi anemia and the underlying causes of genomic instability</article-title>. <source>Environ Mol Mutagenesis</source> (<year>2020</year>) <volume>61</volume>:<fpage>693</fpage>&#x2013;<lpage>708</lpage>. <pub-id pub-id-type="doi">10.1002/em.22358</pub-id>
</citation>
</ref>
<ref id="B67">
<label>67.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fiesco-Roa</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Giri</surname>
<given-names>N</given-names>
</name>
<name>
<surname>McReynolds</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Best</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Alter</surname>
<given-names>BP</given-names>
</name>
</person-group>. <article-title>Genotype-phenotype associations in Fanconi anemia: a literature review</article-title>. <source>Blood Rev</source> (<year>2019</year>) <volume>37</volume>:<fpage>100589</fpage>&#x2013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/j.blre.2019.100589</pub-id>
</citation>
</ref>
<ref id="B68">
<label>68.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Webster</surname>
<given-names>ALH</given-names>
</name>
<name>
<surname>Sanders</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Pater</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Dietrich</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Noonan</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Lach</surname>
<given-names>FP</given-names>
</name>
<etal/>
</person-group> <article-title>Genomic signature of Fanconi anemia DNA repair pathway deficiency in cancer</article-title>. <source>Nature</source> (<year>2022</year>) <volume>612</volume>:<fpage>495</fpage>&#x2013;<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-022-05253-4</pub-id>
</citation>
</ref>
<ref id="B69">
<label>69.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sridharan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>MW</given-names>
</name>
</person-group>. <article-title>Knockdown of &#xb5;-calpain in Fanconi anemia, FA-A, cells by siRNA restores &#x3b1;II spectrin levels and corrects chromosomal instability and defective DNA interstrand cross-link repair</article-title>. <source>Biochemistry</source> (<year>2010</year>) <volume>49</volume>:<fpage>5570</fpage>&#x2013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1021/bi100656j</pub-id>
</citation>
</ref>
<ref id="B70">
<label>70.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lefferts</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>MW</given-names>
</name>
</person-group>. <article-title>Fanconi anemia cell lines deficient in &#x3b1;II spectrin express normal levels of &#x3b1;II spectrin mRNA</article-title>. <source>Biochem Biophysical Res Commun</source> (<year>2003</year>) <volume>307</volume>:<fpage>510</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/s0006-291x(03)01213-0</pub-id>
</citation>
</ref>
<ref id="B71">
<label>71.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grum</surname>
<given-names>VL</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D</given-names>
</name>
<name>
<surname>MacDonald</surname>
<given-names>RI</given-names>
</name>
<name>
<surname>Mondragon</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Structures of two repeats of spectrin suggest models of flexibility</article-title>. <source>Cell</source> (<year>1999</year>) <volume>98</volume>:<fpage>523</fpage>&#x2013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/s0092-8674(00)81980-7</pub-id>
</citation>
</ref>
<ref id="B72">
<label>72.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Spectrin: structure, function and disease</article-title>. <source>Sci China Life Sci</source> (<year>2013</year>) <volume>56</volume>:<fpage>1076</fpage>&#x2013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1007/s11427-013-4575-0</pub-id>
</citation>
</ref>
<ref id="B73">
<label>73.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morrow</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Marchesi</surname>
<given-names>VT</given-names>
</name>
</person-group>. <article-title>Self-assembly of spectrin oligomers <italic>in vitro</italic>: a basis for a dynamic cytoskeleton</article-title>. <source>The J Cel Biol</source> (<year>1981</year>) <volume>88</volume>:<fpage>463</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.88.2.463</pub-id>
</citation>
</ref>
<ref id="B74">
<label>74.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cesareni</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Panni</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nardelli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Castagnoli</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Can we infer peptide recognition specificity mediated by SH3 domains?</article-title> <source>FEBS Lett</source> (<year>2002</year>) <volume>513</volume>:<fpage>38</fpage>&#x2013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/s0014-5793(01)03307-5</pub-id>
</citation>
</ref>
<ref id="B75">
<label>75.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicolas</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Fournier</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Galand</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Malbert-Colas</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bournier</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Kroviarski</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group> <article-title>Tyrosine phosphorylation regulates alpha II spectrin cleavage by calpain</article-title>. <source>Mol Cell Biol</source> (<year>2002</year>) <volume>22</volume>:<fpage>3527</fpage>&#x2013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1128/mcb.22.10.3527-3536.2002</pub-id>
</citation>
</ref>
<ref id="B76">
<label>76.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nedrelow</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Cianci</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Morrow</surname>
<given-names>JS</given-names>
</name>
</person-group>. <article-title>C-Src binds &#x3b1;II spectrin&#x2019;s Src homology 3 (SH3) domain and blocks calpain susceptibility by phosphorylating Tyr1176</article-title>. <source>J Biol Chem</source> (<year>2003</year>) <volume>278</volume>:<fpage>7735</fpage>&#x2013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.m210988200</pub-id>
</citation>
</ref>
<ref id="B77">
<label>77.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ackermann</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brieger</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>The role of nonerythroid spectrin &#x3b1;II in cancer</article-title>. <source>J Oncol</source> (<year>2019</year>) <volume>2019</volume>:<fpage>7079604</fpage>. <pub-id pub-id-type="doi">10.1155/2019/7079604</pub-id>
</citation>
</ref>
<ref id="B78">
<label>78.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ziemnicka-Kotula</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Potempska</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>EC</given-names>
</name>
<etal/>
</person-group> <article-title>Identification of a candidate human spectrin Src homology 3 domainbinding protein suggests a general mechanism of association of tyrosine kinases with the spectrin-based membrane skeleton</article-title>. <source>J Biol Chem</source> (<year>1998</year>) <volume>273</volume>:<fpage>13681</fpage>&#x2013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.273.22.13681</pub-id>
</citation>
</ref>
<ref id="B79">
<label>79.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mayer</surname>
<given-names>BJ</given-names>
</name>
</person-group>. <article-title>SH3 domains: complexity in moderation</article-title>. <source>J Cell Sci</source> (<year>2001</year>) <volume>114</volume>:<fpage>1253</fpage>&#x2013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.114.7.1253</pub-id>
</citation>
</ref>
<ref id="B80">
<label>80.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ren</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mayer</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Cicchetti</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Baltimore</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Identification of a ten-amino acid proline-rich SH3 binding site</article-title>. <source>Science</source> (<year>1993</year>) <volume>259</volume>:<fpage>1157</fpage>&#x2013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1126/science.8438166</pub-id>
</citation>
</ref>
<ref id="B81">
<label>81.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kay</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Williamson</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Sudol</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains</article-title>. <source>FASEB J</source> (<year>2000</year>) <volume>14</volume>:<fpage>231</fpage>&#x2013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1096/fasebj.14.2.231</pub-id>
</citation>
</ref>
<ref id="B82">
<label>82.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rotter</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kroviarski</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nicolas</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Dhermy</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lecomte</surname>
<given-names>MC</given-names>
</name>
</person-group>. <article-title>AlphaII-spectrin is an <italic>in vitro</italic> target for caspase-2, and its cleavage is regulated by calmodulin binding</article-title>. <source>Biochem J</source> (<year>2004</year>) <volume>378</volume>:<fpage>161</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1042/BJ20030955</pub-id>
</citation>
</ref>
<ref id="B83">
<label>83.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harris</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Croall</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Morrow</surname>
<given-names>JS</given-names>
</name>
</person-group>. <article-title>Calmodulin regulates fodrin susceptibility to cleavage by calcium-dependent protease I</article-title>. <source>J Biol Chem</source> (<year>1989</year>) <volume>264</volume>:<fpage>17401</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/s0021-9258(18)71508-1</pub-id>
</citation>
</ref>
<ref id="B84">
<label>84.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simonovic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Cianci</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Steitz</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Morrow</surname>
<given-names>JS</given-names>
</name>
</person-group>. <article-title>Structure of the calmodulin &#x3b1;II-spectrin complex provides insight into the regulation of cell plasticity</article-title>. <source>J Biol Chem</source> (<year>2006</year>) <volume>281</volume>:<fpage>34333</fpage>&#x2013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.m604613200</pub-id>
</citation>
</ref>
<ref id="B85">
<label>85.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sangerman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M</given-names>
</name>
<name>
<surname>brough</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Goodman</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Essential control of an endothelial cell ISOC by the spectrin membrane skeleton</article-title>. <source>The J Cell Biol</source> (<year>2001</year>) <volume>154</volume>:<fpage>1225</fpage>&#x2013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.200106156</pub-id>
</citation>
</ref>
<ref id="B86">
<label>86.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bennett</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Healy</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Organizing the fluid membrane bilayer: diseases linked to spectrin and ankyrin</article-title>. <source>Trends Mol Med</source> (<year>2008</year>) <volume>14</volume>:<fpage>28</fpage>&#x2013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmed.2007.11.005</pub-id>
</citation>
</ref>
<ref id="B87">
<label>87.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Unsain</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Stefani</surname>
<given-names>FD</given-names>
</name>
<name>
<surname>Caceres</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>The actin/spectrin membrane-associated periodic skeleton in neurons</article-title>. <source>Front Synaptic Neurosci</source> (<year>2018</year>) <volume>10</volume>:<fpage>10</fpage>. <pub-id pub-id-type="doi">10.3389/fnsyn.2018.00010</pub-id>
</citation>
</ref>
<ref id="B88">
<label>88.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhuang</surname>
<given-names>X</given-names>
</name>
</person-group>. <article-title>Structural organization of the actin-spectrinbased membrane skeleton in dendrites and soma of neurons</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2017</year>) <volume>114</volume>:<fpage>E6678-E6685</fpage>&#x2013;<lpage>E6685</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1705043114</pub-id>
</citation>
</ref>
<ref id="B89">
<label>89.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Machnicka</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Grochowalska</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Boguslawska</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Sikorski</surname>
<given-names>AF</given-names>
</name>
</person-group>. <article-title>The role of spectrin in cell adhesion and cell-cell contact</article-title>. <source>Exp Biol &#x26; Med</source> (<year>2019</year>) <volume>244</volume>:<fpage>13011312</fpage>. <pub-id pub-id-type="doi">10.1177/1535370219859003</pub-id>
</citation>
</ref>
<ref id="B90">
<label>90.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bialkowska</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Saido</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>j</given-names>
</name>
</person-group>. <article-title>SH3 domain of spectrin participates in the activation of Rac in specialized calpain-induced integrin signaling complexes</article-title>. <source>J Cell Sci</source> (<year>2005</year>) <volume>118</volume>:<fpage>381</fpage>&#x2013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.01625</pub-id>
</citation>
</ref>
<ref id="B91">
<label>91.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rotter</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bournier</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Nicolas</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Dhermy</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lecomte</surname>
<given-names>M-C</given-names>
</name>
</person-group>. <article-title>&#x3b1;II-Spectrin interacts with Tes and EVL, two actin-binding proteins located at cell contacts</article-title>. <source>Biochem J</source> (<year>2005</year>) <volume>388</volume>:<fpage>631</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1042/bj20041502</pub-id>
</citation>
</ref>
<ref id="B92">
<label>92.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Godi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Santone</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Pertile</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Devarajan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Stabach</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Morrow</surname>
<given-names>JS</given-names>
</name>
<etal/>
</person-group> <article-title>ADP ribosylation factor regulates spectrin binding to the Golgi complex</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>1998</year>) <volume>95</volume>:<fpage>8607</fpage>&#x2013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.95.15.8607</pub-id>
</citation>
</ref>
<ref id="B93">
<label>93.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levine</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Willard</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Fodrin: axonally transported polypeptides associated with the internal periphery of many cells</article-title>. <source>The J Cel Biol</source> (<year>1981</year>) <volume>90</volume>:<fpage>631</fpage>&#x2013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.90.3.631</pub-id>
</citation>
</ref>
<ref id="B94">
<label>94.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holleran</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Ligon</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Tokito</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stankewich</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Morrow</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Holzbaur</surname>
<given-names>ELF</given-names>
</name>
</person-group>. <article-title>&#x3b2;III spectrin binds to the Arp1 subunit of dynactin</article-title>. <source>J Biol Chem</source> (<year>2001</year>) <volume>276</volume>:<fpage>36598</fpage>&#x2013;<lpage>605</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.m104838200</pub-id>
</citation>
</ref>
<ref id="B95">
<label>95.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirokawa</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Noda</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Niwa</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Kinesin superfamily motor proteins and intracellular transport</article-title>. <source>Nat Rev Mol Cell Biol</source> (<year>2009</year>) <volume>10</volume>:<fpage>682</fpage>&#x2013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1038/nrm2774</pub-id>
</citation>
</ref>
<ref id="B96">
<label>96.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takeda</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yamazaki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Seog</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Kanai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Terada</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hirokawa</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Kinesin superfamily protein 3 (KIF3) motor transports fodrin-associating vesicles important for neurite building</article-title>. <source>J Cell Biol</source> (<year>2000</year>) <volume>148</volume>:<fpage>1255</fpage>&#x2013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.148.6.1255</pub-id>
</citation>
</ref>
<ref id="B97">
<label>97.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sikorski</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Terlecki</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Zagon</surname>
<given-names>IS</given-names>
</name>
<name>
<surname>Goodman</surname>
<given-names>SR</given-names>
</name>
</person-group>. <article-title>Synapsin I-mediated interaction of brain spectrin with synaptic vesicles</article-title>. <source>The J Cel Biol</source> (<year>1991</year>) <volume>114</volume>:<fpage>313</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.114.2.313</pub-id>
</citation>
</ref>
<ref id="B98">
<label>98.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watabe</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Valencia</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Le Pape</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Yamaguchi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rouzaud</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group> <article-title>Involvement of dynein and spectrin with early melanosome transport and melanosomal protein trafficking</article-title>. <source>J Invest Dermatol</source> (<year>2008</year>) <volume>128</volume>:<fpage>162</fpage>&#x2013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1038/sj.jid.5701019</pub-id>
</citation>
</ref>
<ref id="B99">
<label>99.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Goodman</surname>
<given-names>SR</given-names>
</name>
</person-group>. <article-title>Spectrin and ubiquitination: a review</article-title>. <source>Cell Mol Biol (Noisy-le-Grand, France)</source> (<year>2005</year>) <volume>Suppl 51</volume>:<fpage>OL801</fpage>&#x2013;<lpage>OL807</lpage>.</citation>
</ref>
<ref id="B100">
<label>100.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sangerman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kakhniashvili</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shartava</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Goodman</surname>
<given-names>SR</given-names>
</name>
</person-group>. <article-title>Spectrin ubiquitination and oxidative stress: potential roles in blood and neurological disorders</article-title>. <source>Cell &#x26; Mol Biol Lett</source> (<year>2001</year>) <volume>6</volume>:<fpage>607</fpage>&#x2013;<lpage>36</lpage>.</citation>
</ref>
<ref id="B101">
<label>101.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lefferts</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sridharan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Baralt</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>MW</given-names>
</name>
</person-group>. <article-title>The SH3 domain of &#x3b1;II spectrin is a target for the fanconi anemia protein, FANCG</article-title>. <source>Biochemistry</source> (<year>2009</year>) <volume>48</volume>:<fpage>254</fpage>&#x2013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1021/bi801483u</pub-id>
</citation>
</ref>
<ref id="B102">
<label>102.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holaska</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>KL</given-names>
</name>
</person-group>. <article-title>An emerin &#x201c;Proteome&#x201d;: purification of distinct emerin-containing complexes from HeLa cells suggests molecular basis for diverse roles including gene regulation, mRNA splicing, signaling, mechanosensing, and nuclear architecture</article-title>. <source>Biochemistry</source> (<year>2007</year>) <volume>46</volume>:<fpage>8897</fpage>&#x2013;<lpage>908</lpage>. <pub-id pub-id-type="doi">10.1021/bi602636m</pub-id>
</citation>
</ref>
<ref id="B103">
<label>103.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faridounnia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Folkers</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Boelens</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Function and interactions of ERCC1-XPF in DNA damage response</article-title>. <source>Molecules</source> (<year>2018</year>) <volume>23</volume>:<fpage>3205</fpage>. <pub-id pub-id-type="doi">10.3390/molecules23123205</pub-id>
</citation>
</ref>
<ref id="B104">
<label>104.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoogenboom</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Boonen</surname>
<given-names>RACM</given-names>
</name>
<name>
<surname>Knipscheer</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>The role of SLX4 and its associated nucleases in DNA interstrand crosslink repair</article-title>. <source>Nucleic Acids Res</source> (<year>2019</year>) <volume>47</volume>:<fpage>2377</fpage>&#x2013;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky1276</pub-id>
</citation>
</ref>
<ref id="B105">
<label>105.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group> <article-title>SLX4IP acts with SLX4 and XPF&#x2013;ERCC1 to promote interstrand crosslink repair</article-title>. <source>Nucleic Acids Res</source> (<year>2019</year>) <volume>47</volume>:<fpage>10181</fpage>&#x2013;<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkz769</pub-id>
</citation>
</ref>
<ref id="B106">
<label>106.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Semlow</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Walter</surname>
<given-names>JC</given-names>
</name>
</person-group>. <article-title>Mechanisms of vertebrate DNA interstrand cross-link repair</article-title>. <source>Annu Rev Biochem</source> (<year>2021</year>) <volume>90</volume>:<fpage>107</fpage>&#x2013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-biochem-080320-112510</pub-id>
</citation>
</ref>
<ref id="B107">
<label>107.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Coyne</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Dubreuil</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Branton</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Cell shape and interaction defects in alpha-spectrin mutants of <italic>Drosophila melanogaster</italic>
</article-title>. <source>The J Cel Biol</source> (<year>1993</year>) <volume>123</volume>:<fpage>1797</fpage>&#x2013;<lpage>809</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.123.6.1797</pub-id>
</citation>
</ref>
<ref id="B108">
<label>108.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Norman</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Moerman</surname>
<given-names>DG</given-names>
</name>
</person-group>. <article-title>&#x391; Spectrin is essential for morphogenesis and body wall muscle formation in <italic>Caenorhabditis elegans</italic>
</article-title>. <source>The J Cell Biol</source> (<year>2002</year>) <volume>157</volume>:<fpage>665</fpage>&#x2013;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.200111051</pub-id>
</citation>
</ref>
<ref id="B109">
<label>109.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Jing</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>MicroRNA-128-3p regulates mitomycin C-induced DNA damage response in lung cancer cells through repressing<italic>SPTAN1</italic>
</article-title>. <source>Oncotarget</source> (<year>2017</year>) <volume>8</volume>:<fpage>58098</fpage>&#x2013;<lpage>107</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.12300</pub-id>
</citation>
</ref>
<ref id="B110">
<label>110.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McPherson</surname>
<given-names>PS</given-names>
</name>
</person-group>. <article-title>Regulatory role of SH3 domain-mediated protein-protein interactions in synaptic vesicle endocytosis</article-title>. <source>Cell Signal</source> (<year>1999</year>) <volume>11</volume>:<fpage>229</fpage>&#x2013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/s0898-6568(98)00059-x</pub-id>
</citation>
</ref>
<ref id="B111">
<label>111.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>D&#x2019;Andrea</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Regan</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>TPR proteins: the versatile helix</article-title>. <source>Trends Biochem Sci</source> (<year>2003</year>) <volume>28</volume>:<fpage>655</fpage>&#x2013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2003.10.007</pub-id>
</citation>
</ref>
<ref id="B112">
<label>112.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blatch</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Lassle</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>The tetratricopeptide repeat: a structural motif mediating protein-protein interactions</article-title>. <source>Bioessays</source> (<year>1999</year>) <volume>21</volume>:<fpage>932</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1002/(sici)1521-1878(199911)21:11&#x3c;932::aid-bies5&#x3e;3.0.co;2-n</pub-id>
</citation>
</ref>
<ref id="B113">
<label>113.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blom</surname>
<given-names>E</given-names>
</name>
<name>
<surname>van de Vrugt</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Vries</surname>
<given-names>Yd</given-names>
</name>
<name>
<surname>de Winter</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Arwert</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Joenje</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Multiple TPR motifs characterize the Fanconi anemia FANCG protein</article-title>. <source>DNA Repair</source> (<year>2004</year>) <volume>3</volume>:<fpage>77</fpage>&#x2013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.dnarep.2003.09.007</pub-id>
</citation>
</ref>
<ref id="B114">
<label>114.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hussain</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Blom</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Sung</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>SM</given-names>
</name>
<etal/>
</person-group> <article-title>Tetratricopeptide-motif-mediated interaction of FANCG with recombination proteins XRCC3 and BRCA2</article-title>. <source>DNA Repair</source> (<year>2006</year>) <volume>5</volume>:<fpage>629</fpage>&#x2013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.dnarep.2006.02.007</pub-id>
</citation>
</ref>
<ref id="B115">
<label>115.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>MW</given-names>
</name>
</person-group>. <article-title>The Fanconi anemia protein, FANCG, binds to the ERCC1-XPF endonuclease via its tetratricopeptide repeats and the central domain of ERCC1</article-title>. <source>Biochemistry</source> (<year>2010</year>) <volume>49</volume>:<fpage>5560</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1021/bi100584c</pub-id>
</citation>
</ref>
<ref id="B116">
<label>116.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Laat</surname>
<given-names>WL</given-names>
</name>
<name>
<surname>Sijbers</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Odijk</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Jaspers</surname>
<given-names>NG</given-names>
</name>
<name>
<surname>Hoeijmakers</surname>
<given-names>JH</given-names>
</name>
</person-group>. <article-title>Mapping of interaction domains between human repair proteins ERCC1 and XPF</article-title>. <source>Nucleic Acids Res</source> (<year>1998</year>) <volume>26</volume>:<fpage>4146</fpage>&#x2013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1093/nar/26.18.4146</pub-id>
</citation>
</ref>
<ref id="B117">
<label>117.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tripsianes</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Folkers</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Ab</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Odijk</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Jaspers</surname>
<given-names>NGJ</given-names>
</name>
<etal/>
</person-group> <article-title>The structure of the human ERCC1/XPF interaction domains reveals a complementary role for the two proteins in nucleotide excision repair</article-title>. <source>Structure</source> (<year>2005</year>) <volume>13</volume>:<fpage>1849</fpage>&#x2013;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1016/j.str.2005.08.014</pub-id>
</citation>
</ref>
<ref id="B118">
<label>118.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Ryu</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Chae</surname>
<given-names>YK</given-names>
</name>
<name>
<surname>Pelton</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Wemmer</surname>
<given-names>DE</given-names>
</name>
<etal/>
</person-group> <article-title>Biophysical characterization of the interaction domains and mapping of the contact residues in the XPF-ERCC1 complex</article-title>. <source>J Biol Chem</source> (<year>2005</year>) <volume>280</volume>:<fpage>28644</fpage>&#x2013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.m501083200</pub-id>
</citation>
</ref>
<ref id="B119">
<label>119.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Das</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Faridounnia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kovacic</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kaptein</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Boelens</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Folkers</surname>
<given-names>GE</given-names>
</name>
</person-group>. <article-title>Singlestranded DNA binding by the helix-hairpin-helix domain of XPF protein contributes to the substrate specificity of the ERCC1-XPF protein complex</article-title>. <source>J Biol Chem</source> (<year>2017</year>) <volume>292</volume>:<fpage>2842</fpage>&#x2013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.m116.747857</pub-id>
</citation>
</ref>
<ref id="B120">
<label>120.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akkari</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Bateman</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Reifsteck</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Grompe</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>DNA replication is required to elicit cellular responses to psoralen-induced DNA interstrand cross-links</article-title>. <source>Mol Cell Biol</source> (<year>2000</year>) <volume>20</volume>:<fpage>8283</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1128/mcb.20.21.8283-8289.2000</pub-id>
</citation>
</ref>
<ref id="B121">
<label>121.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raschle</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Knipscheer</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Enoiu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Angelov</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Griffith</surname>
<given-names>JD</given-names>
</name>
<etal/>
</person-group> <article-title>Mechanism of replication-coupled DNA interstrand crosslink repair</article-title>. <source>Cell</source> (<year>2008</year>) <volume>134</volume>:<fpage>969</fpage>&#x2013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2008.08.030</pub-id>
</citation>
</ref>
<ref id="B122">
<label>122.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Gottesman</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Gautier</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>The differences between ICL repair during and outside of S phase</article-title>. <source>Trends Biochem Sci</source> (<year>2013</year>) <volume>38</volume>:<fpage>386</fpage>&#x2013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2013.05.004</pub-id>
</citation>
</ref>
<ref id="B123">
<label>123.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taniguchi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Garcia-Higuera</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Andreassen</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Gregory</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Grompe</surname>
<given-names>M</given-names>
</name>
<name>
<surname>D&#x2019;Andrea</surname>
<given-names>AD</given-names>
</name>
</person-group>. <article-title>S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51</article-title>. <source>Blood</source> (<year>2002</year>) <volume>100</volume>:<fpage>2414</fpage>&#x2013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2002-01-0278</pub-id>
</citation>
</ref>
<ref id="B124">
<label>124.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knipscheer</surname>
<given-names>P</given-names>
</name>
<name>
<surname>R&#xe4;schle</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Smogorzewska</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Enoiu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>TV</given-names>
</name>
<name>
<surname>Scharer</surname>
<given-names>OD</given-names>
</name>
<etal/>
</person-group> <article-title>The Fanconi anemia pathway promotes replicationdependent DNA interstrand cross-link repair</article-title>. <source>Science</source> (<year>2009</year>) <volume>326</volume>:<fpage>1698</fpage>&#x2013;<lpage>701</lpage>. <pub-id pub-id-type="doi">10.1126/science.1182372</pub-id>
</citation>
</ref>
<ref id="B125">
<label>125.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Renaudin</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Rosselli</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>The FANC/BRCA pathway releases replication blockades by eliminating DNA interstrand cross-links</article-title>. <source>Genes</source> (<year>2020</year>) <volume>11</volume>:<fpage>585</fpage>. <pub-id pub-id-type="doi">10.3390/genes11050585</pub-id>
</citation>
</ref>
<ref id="B126">
<label>126.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amunugama</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Willcox</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Abdullah</surname>
<given-names>UB</given-names>
</name>
<name>
<surname>El-Sagheer</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>Replication fork reversal during DNA interstrand crosslink repair requires CMG unloading</article-title>. <source>Cell Rep</source> (<year>2018</year>) <volume>23</volume>:<fpage>3419</fpage>&#x2013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2018.05.061</pub-id>
</citation>
</ref>
<ref id="B127">
<label>127.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bellani</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Thazhathveetil</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Ling</surname>
<given-names>C</given-names>
</name>
<name>
<surname>de&#xa0;Winter</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>The DNA translocase FANCM/MHF promotes replication traverse of DNA interstrand crosslinks</article-title>. <source>Mol Cell</source> (<year>2013</year>) <volume>52</volume>(<issue>52</issue>):<fpage>434</fpage>&#x2013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2013.09.021</pub-id>
</citation>
</ref>
<ref id="B128">
<label>128.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klein Douwel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Boonen</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Szypowska</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Raschle</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Walter</surname>
<given-names>JC</given-names>
</name>
<etal/>
</person-group> <article-title>XPF-ERCC1 acts in unhooking DNA interstrand crosslinks in cooperation with FANCD2 and FANCP/SLX4</article-title>. <source>Mol Cell</source> (<year>2014</year>) <volume>54</volume>:<fpage>460</fpage>&#x2013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2014.03.015</pub-id>
</citation>
</ref>
<ref id="B129">
<label>129.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guervilly</surname>
<given-names>J-H</given-names>
</name>
<name>
<surname>Gaillard</surname>
<given-names>PH</given-names>
</name>
</person-group>. <article-title>SLX4: multitasking to maintain genome stability</article-title>. <source>Crit Rev Biochem Mol Biol</source> (<year>2018</year>) <volume>53</volume>:<fpage>475</fpage>&#x2013;<lpage>514</lpage>. <pub-id pub-id-type="doi">10.1080/10409238.2018.1488803</pub-id>
</citation>
</ref>
<ref id="B130">
<label>130.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trakselis</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Seidman</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Brosh</surname>
<given-names>RM</given-names>
<suffix>Jr</suffix>
</name>
</person-group>. <article-title>Mechanistic insights into how CMG helicase facilitates replication past DNA roadblocks</article-title>. <source>DNA Repair</source> (<year>2017</year>) <volume>55</volume>:<fpage>76</fpage>&#x2013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.dnarep.2017.05.005</pub-id>
</citation>
</ref>
<ref id="B131">
<label>131.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ling</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ohzeki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ishiai</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Bloom syndrome complex promotes FANCM recruitment to stalled replication forks and facilitates both repair and traverse of DNA interstrand crosslinks</article-title>. <source>Cell Discov</source> (<year>2016</year>) <volume>2</volume>:<fpage>16047</fpage>. <pub-id pub-id-type="doi">10.1038/celldisc.2016.47</pub-id>
</citation>
</ref>
<ref id="B132">
<label>132.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huh</surname>
<given-names>GY</given-names>
</name>
<name>
<surname>Glantz</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Je</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Morrow</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JH</given-names>
</name>
</person-group>. <article-title>Calpain proteolysis of &#x3b1;II-spectrin in the normal adult human brain</article-title>. <source>Neurosci Lett</source> (<year>2001</year>) <volume>316</volume>:<fpage>41</fpage>&#x2013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/s0304-3940(01)02371-0</pub-id>
</citation>
</ref>
<ref id="B133">
<label>133.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pike</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Flint</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dutta</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>KKW</given-names>
</name>
<name>
<surname>Hayes</surname>
<given-names>RL</given-names>
</name>
</person-group>. <article-title>Accumulation of non-erythroid &#x3b1;II-spectrin and calpain-cleaved &#x3b1;II-spectrin breakdown products in cerebrospinal fluid after traumatic brain injury in rats</article-title>. <source>J Neurochem</source> (<year>2001</year>) <volume>78</volume>:<fpage>1297</fpage>&#x2013;<lpage>306</lpage>. <pub-id pub-id-type="doi">10.1046/j.1471-4159.2001.00510.x</pub-id>
</citation>
</ref>
<ref id="B134">
<label>134.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Baudry</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Brain fodrin: substrate for calpain I, an endogenous calcium-activated protease</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>1984</year>) <volume>81</volume>:<fpage>3572</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.81.11.3572</pub-id>
</citation>
</ref>
<ref id="B135">
<label>135.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miazek</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zalas</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Skrzymowska</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bogin</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Grzymaj&#x142;o</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Goszczynski</surname>
<given-names>TM</given-names>
</name>
<etal/>
</person-group> <article-title>Age-dependent ataxia and neurodegeneration caused by an &#x3b1;II spectrin mutation with impaired regulation of its calpain sensitivity</article-title>. <source>Scientific Rep</source> (<year>2021</year>) <volume>11</volume>:<fpage>7312</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-021-86470-1</pub-id>
</citation>
</ref>
<ref id="B136">
<label>136.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Lopez-Martinez</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Nicholson</surname>
<given-names>WV</given-names>
</name>
<name>
<surname>Venien-Bryan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cohn</surname>
<given-names>MA</given-names>
</name>
</person-group>. <article-title>The FANCD2-FANCI complex is recruited to DNA interstrand crosslinks before monoubiquitination of FANCD2</article-title>. <source>Nat Commun</source> (<year>2016</year>) <volume>7</volume>:<fpage>12124</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms12124</pub-id>
</citation>
</ref>
<ref id="B137">
<label>137.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Deans</surname>
<given-names>AJ</given-names>
</name>
</person-group>. <article-title>Structural insight into FANCI-FANCD2 monoubiquitination</article-title>. <source>Essays Biochem</source> (<year>2020</year>) <volume>64</volume>:<fpage>807</fpage>&#x2013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1042/ebc20200001</pub-id>
</citation>
</ref>
<ref id="B138">
<label>138.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>W</given-names>
</name>
<name>
<surname>van Twest</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Leis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bythell-Douglas</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>VJ</given-names>
</name>
<name>
<surname>Sharp</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Monoubiquitination by the human Fanconi anemia core complex clamps FANCI:FANCD2 on DNA in filamentous arrays</article-title>. <source>Elife</source> (<year>2020</year>) <volume>9</volume>:<fpage>e54128</fpage>. <pub-id pub-id-type="doi">10.7554/elife.54128</pub-id>
</citation>
</ref>
<ref id="B139">
<label>139.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alcon</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kaczmarczk</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Ray</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Liolios</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Guilbaud</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sijacki</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group> <article-title>FANCD2-FANCI surveys DNA and recognizes double-to single-stranded junctions</article-title>. <source>Nature</source> (<year>2023</year>) <volume>632</volume>:<fpage>1165</fpage>&#x2013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-024-07770-w</pub-id>
</citation>
</ref>
<ref id="B140">
<label>140.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Czogalla</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sikorski</surname>
<given-names>AF</given-names>
</name>
</person-group>. <article-title>Spectrin and calpain: a &#x2018;target&#x2019; and a &#x2018;sniper&#x2019; in the pathology of neuronal cells</article-title>. <source>Cell Mol Life Sci</source> (<year>2005</year>) <volume>62</volume>:<fpage>1913</fpage>&#x2013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-005-5097-0</pub-id>
</citation>
</ref>
<ref id="B141">
<label>141.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vanderklish</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Bahr</surname>
<given-names>BA</given-names>
</name>
</person-group>. <article-title>The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states</article-title>. <source>Int J Exp Pathol</source> (<year>2000</year>) <volume>81</volume>:<fpage>323</fpage>&#x2013;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2613.2000.00169.x</pub-id>
</citation>
</ref>
<ref id="B142">
<label>142.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faivre</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Guardiola</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dokal</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ebell</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Zatterale</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>Association of complementation group and mutation type with clinical outcome in fanconi anemia. European Fanconi Anemia Research Group</article-title>. <source>Blood</source> (<year>2000</year>) <volume>96</volume>:<fpage>4064</fpage>&#x2013;<lpage>70</lpage>.</citation>
</ref>
<ref id="B143">
<label>143.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siddique</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Nakanishi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Taniguchi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Grompe</surname>
<given-names>M</given-names>
</name>
<name>
<surname>D&#x2019;Andrea</surname>
<given-names>AD</given-names>
</name>
</person-group>. <article-title>Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells</article-title>. <source>Exp Hematol</source> (<year>2001</year>) <volume>29</volume>:<fpage>1448</fpage>&#x2013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/s0301-472x(01)00754-8</pub-id>
</citation>
</ref>
<ref id="B144">
<label>144.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palm</surname>
<given-names>W</given-names>
</name>
<name>
<surname>de Lange</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>How shelterin protects mammalian telomeres</article-title>. <source>Annu Rev Genet</source> (<year>2008</year>) <volume>42</volume>:<fpage>301</fpage>&#x2013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.genet.41.110306.130350</pub-id>
</citation>
</ref>
<ref id="B145">
<label>145.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O&#x2019;Sullivan</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Karlseder</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Telomeres: protecting chromosomes against genome instability</article-title>. <source>Nat Rev Mol Cell Biol</source> (<year>2010</year>) <volume>11</volume>:<fpage>171</fpage>&#x2013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1038/nrm2848</pub-id>
</citation>
</ref>
<ref id="B146">
<label>146.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murnane</surname>
<given-names>JP</given-names>
</name>
</person-group>. <article-title>Telomere dysfunction and chromosome instability</article-title>. <source>Mutat Research/Fundamental Mol Mech Mutagenesis</source> (<year>2012</year>) <volume>730</volume>:<fpage>28</fpage>&#x2013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.mrfmmm.2011.04.008</pub-id>
</citation>
</ref>
<ref id="B147">
<label>147.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Lange</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Shelterin-mediated telomere protection</article-title>. <source>Annu Rev Genet</source> (<year>2018</year>) <volume>52</volume>:<fpage>223</fpage>&#x2013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-genet-032918-021921</pub-id>
</citation>
</ref>
<ref id="B148">
<label>148.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Pendlebury</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Nandakumar</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Structural biology of telomeres and telomerase</article-title>. <source>Cell Mol Life Sci</source> (<year>2020</year>) <volume>77</volume>:<fpage>61</fpage>&#x2013;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-019-03369-x</pub-id>
</citation>
</ref>
<ref id="B149">
<label>149.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roka</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Solomou</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Kattamis</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Telomere biology: from disorders to hematological diseases</article-title>. <source>Front Oncol</source> (<year>2023</year>) <volume>13</volume>:<fpage>1167848</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2023.1167848</pub-id>
</citation>
</ref>
<ref id="B150">
<label>150.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>THD</given-names>
</name>
</person-group>. <article-title>Structural biology of shelterin and telomeric chromatin: the pieces and an unfinished puzzle</article-title>. <source>Biochem Soc Trans</source> (<year>2024</year>) <volume>52</volume>:<fpage>1551</fpage>&#x2013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1042/bst20230300</pub-id>
</citation>
</ref>
<ref id="B151">
<label>151.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smogorzewska</surname>
<given-names>A</given-names>
</name>
<name>
<surname>de Lange</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Regulation of telomerase by telomeric proteins</article-title>. <source>Annu Rev Biochem</source> (<year>2004</year>) <volume>73</volume>:<fpage>177</fpage>&#x2013;<lpage>208</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.biochem.73.071403.160049</pub-id>
</citation>
</ref>
<ref id="B152">
<label>152.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blackburn</surname>
<given-names>EH</given-names>
</name>
</person-group>. <article-title>Telomeres and telomerase</article-title>. <source>The Keio J Med</source> (<year>2000</year>) <volume>49</volume>:<fpage>859</fpage>&#x2013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.2302/kjm.49.59</pub-id>
</citation>
</ref>
<ref id="B153">
<label>153.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stern</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Bryan</surname>
<given-names>TM</given-names>
</name>
</person-group>. <article-title>Telomerase recruitment to telomeres</article-title>. <source>Cytogenet Genome Res</source> (<year>2008</year>) <volume>122</volume>:<fpage>243</fpage>&#x2013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1159/000167810</pub-id>
</citation>
</ref>
<ref id="B154">
<label>154.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>NW</given-names>
</name>
<name>
<surname>Piatyszek</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Prowse</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Harley</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>West</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>PL</given-names>
</name>
<etal/>
</person-group> <article-title>Specific association of human telomerase activity with immortal cells and cancer</article-title>. <source>Science</source> (<year>1994</year>) <volume>266</volume>:<fpage>2011</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1126/science.7605428</pub-id>
</citation>
</ref>
<ref id="B155">
<label>155.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Broccoli</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>de Lange</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Telomerase activity in normal and malignant hematopoietic cells</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>1995</year>) <volume>92</volume>:<fpage>9082</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.92.20.9082</pub-id>
</citation>
</ref>
<ref id="B156">
<label>156.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Barrett</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Andreassen</surname>
<given-names>PR</given-names>
</name>
</person-group>. <article-title>A role for monoubiquitinated FANCD2 at telomeres in ALT cells</article-title>. <source>Nucleic Acids Res</source> (<year>2009</year>) <volume>37</volume>:<fpage>1740</fpage>&#x2013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkn995</pub-id>
</citation>
</ref>
<ref id="B157">
<label>157.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takai</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Smogorzewska</surname>
<given-names>A</given-names>
</name>
<name>
<surname>de Lange</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>DNA damage foci at dysfunctional telomeres</article-title>. <source>Curr Biol</source> (<year>2003</year>) <volume>13</volume>:<fpage>1549</fpage>&#x2013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1016/s0960-9822(03)00542-6</pub-id>
</citation>
</ref>
<ref id="B158">
<label>158.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Thanasoula</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Munoz</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tejera</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McNees</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group> <article-title>Increased telomere fragility and fusions resulting from TRF1 deficiency lead to degenerative pathologies and increased cancer in mice</article-title>. <source>Genes &#x26; Development</source> (<year>2009</year>) <volume>23</volume>:<fpage>2060</fpage>&#x2013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1101/gad.543509</pub-id>
</citation>
</ref>
<ref id="B159">
<label>159.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Blom</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cunningham</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kupfer</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>NJ</given-names>
</name>
</person-group>. <article-title>Several tetratricopeptide repeat (TPR) motifs of FANCG are required for assembly of the BRCA2/D1-D2-G-X3 complex, FANCD2 monoubiquitylation and phleomycin resistance</article-title>. <source>Mutat Research/Fundamental Mol Mech Mutagenesis</source> (<year>2010</year>) <volume>689</volume>:<fpage>12</fpage>&#x2013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.mrfmmm.2010.04.003</pub-id>
</citation>
</ref>
<ref id="B160">
<label>160.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Marriott</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Hussain</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sung</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hoatlin</surname>
<given-names>ME</given-names>
</name>
<etal/>
</person-group> <article-title>FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XR CC3</article-title>. <source>Oncogene</source> (<year>2008</year>) <volume>27</volume>:<fpage>3641</fpage>&#x2013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1211034</pub-id>
</citation>
</ref>
<ref id="B161">
<label>161.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raghunandan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chaudhury</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kellich</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Hanenberg</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Soeback</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>FANCD2, FANCJ and BRCA2 cooperate to promote replication fork recovery independently of the Fanconi anemia complex</article-title>. <source>Cell Cycle</source> (<year>2015</year>) <volume>143</volume>:<fpage>342</fpage>&#x2013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.4161/1538410.2014.987614</pub-id>
</citation>
</ref>
<ref id="B162">
<label>162.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sobeck</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Stone</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hoatlin</surname>
<given-names>ME</given-names>
</name>
</person-group>. <article-title>DNA structure-induced recruitment and activation of the Fanconi anemia pathway protein FANCD2</article-title>. <source>Mol Cell Biol</source> (<year>2007</year>) <volume>27</volume>:<fpage>4283</fpage>&#x2013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1128/mcb.02196-06</pub-id>
</citation>
</ref>
<ref id="B163">
<label>163.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>El Hokayem</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
</person-group>. <article-title>FANCI protein binds to DNA and interacts with FANCD2 to recognize branched structures</article-title>. <source>J Biol Chem</source> (<year>2009</year>) <volume>284</volume>:<fpage>24443</fpage>&#x2013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M109.016006</pub-id>
</citation>
</ref>
<ref id="B164">
<label>164.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Natarajan</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Palitti</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>DNA repair and chromosomal alterations</article-title>. <source>Mutat Research/Genetic Toxicol Environ Mutagenesis</source> (<year>2008</year>) <volume>657</volume>:<fpage>3</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.mrgentox.2008.08.017</pub-id>
</citation>
</ref>
<ref id="B165">
<label>165.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wolqust</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>Cannizzarro</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Rameshjk</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bhattacharuya</surname>
<given-names>PK</given-names>
</name>
<etal/>
</person-group> <article-title>Spectrin isoforms: differential expression in normal hematopoiesis and alterations in neoplastic bone marrow disorders</article-title>. <source>Am J Clin Path</source> (<year>2011</year>) <volume>136</volume>:<fpage>300</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1309/AJCPSA5RNM9IGFJF</pub-id>
</citation>
</ref>
<ref id="B166">
<label>166.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Xi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chai</surname>
<given-names>X</given-names>
</name>
<etal/>
</person-group> <article-title>Spectrins and human diseases</article-title>. <source>Translational Res</source> (<year>2022</year>) <volume>243</volume>:<fpage>78</fpage>&#x2013;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/j.trsl.2021.12.009</pub-id>
</citation>
</ref>
<ref id="B167">
<label>167.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gorman</surname>
<given-names>EB</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Albanese</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ratech</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Patterns of spectrin expression in B-cell lymphomas: loss of spectrin isoforms is associated with nodule-forming and germinal center-related lymphomas</article-title>. <source>Mod Pathol</source> (<year>2007</year>) <volume>20</volume>:<fpage>1245</fpage>&#x2013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1038/modpathol.3800962</pub-id>
</citation>
</ref>
<ref id="B168">
<label>168.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoover</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Turcotte</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Phelan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Barbus</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rayannavar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>BS</given-names>
</name>
<etal/>
</person-group> <article-title>Longitudinal clinical manifestations of Fanconi anemia: a systematized review</article-title>. <source>Blood Rev</source> (<year>2024</year>) <volume>68</volume>:<fpage>101225</fpage>. <pub-id pub-id-type="doi">10.1016/j.blre.2024.101225</pub-id>
</citation>
</ref>
<ref id="B169">
<label>169.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tohyama</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nakashima</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nabatame</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gaik-Siew</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Miyata</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rener-Primec</surname>
<given-names>Z</given-names>
</name>
<etal/>
</person-group> <article-title>SPTAN1 encephalopathy: distinct phenotypes and genotypes</article-title>. <source>J Hum Genet</source> (<year>2015</year>) <volume>60</volume>:<fpage>167</fpage>&#x2013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1038/jhg.2015.5</pub-id>
</citation>
</ref>
<ref id="B170">
<label>170.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riederer</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Zagon</surname>
<given-names>IS</given-names>
</name>
<name>
<surname>Goodman</surname>
<given-names>SR</given-names>
</name>
</person-group>. <article-title>Brain spectrin(240/235) and brain spectrin(240/235E): differential expression during mouse brain development</article-title>. <source>J Neurosci</source> (<year>1987</year>) <volume>7</volume>:<fpage>864</fpage>&#x2013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.07-03-00864.1987</pub-id>
</citation>
</ref>
<ref id="B171">
<label>171.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zagon</surname>
<given-names>IS</given-names>
</name>
<name>
<surname>Riederer</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Goodman</surname>
<given-names>SR</given-names>
</name>
</person-group>. <article-title>Spectrin expression during mammalian brain ontogeny</article-title>. <source>Brain Res Bull</source> (<year>1987</year>) <volume>18</volume>:<fpage>799</fpage>&#x2013;<lpage>807</lpage>. <pub-id pub-id-type="doi">10.1016/0361-9230(87)90219-x</pub-id>
</citation>
</ref>
<ref id="B172">
<label>172.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zimmer</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zagon</surname>
<given-names>IS</given-names>
</name>
<name>
<surname>Goodman</surname>
<given-names>SR</given-names>
</name>
</person-group>. <article-title>Developmental expression of brain beta-spectrin isoform messenger RNAs</article-title>. <source>Brain Res</source> (<year>1992</year>) <volume>594</volume>:<fpage>75</fpage>&#x2013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/0006-8993(92)91030-i</pub-id>
</citation>
</ref>
<ref id="B173">
<label>173.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartlett</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wells</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sabulski</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fuller</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group> <article-title>Fanconi anemia neuroinflammatory syndrome: brain lesions and neurologic injury in Fanconi anemia</article-title>. <source>Blood Adv</source> (<year>2024</year>) <volume>8</volume>:<fpage>3027</fpage>&#x2013;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1182/bloodadvances.2024012577</pub-id>
</citation>
</ref>
<ref id="B174">
<label>174.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Glanowska</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>GG</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>PM</given-names>
</name>
<etal/>
</person-group> <article-title>Critical roles of &#x3b1;II spectrin in brain development and epileptic encephalopathy</article-title>. <source>J Clin Invest</source> (<year>2018</year>) <volume>128</volume>:<fpage>760</fpage>&#x2013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1172/JCI95743</pub-id>
</citation>
</ref>
<ref id="B175">
<label>175.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saitsu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tohyama</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kumada</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Egawa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hamada</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Okada</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group> <article-title>Dominant-negative mutations in &#x3b1;-II spectrin cause West syndrome with severe cerebral hypomyelination, spastic quadriplegia, and developmental delay</article-title>. <source>The Am J Hum Genet</source> (<year>2010</year>) <volume>86</volume>:<fpage>881</fpage>&#x2013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2010.04.013</pub-id>
</citation>
</ref>
<ref id="B176">
<label>176.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Syrbe</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Harms</surname>
<given-names>FL</given-names>
</name>
<name>
<surname>Parrini</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Montomoli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mutze</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Helbig</surname>
<given-names>KL</given-names>
</name>
<etal/>
</person-group> <article-title>Delineating SPTAN1 associated phenotypes: from isolated epilepsy to encephalopathy with progressive brain atrophy</article-title>. <source>Brain</source> (<year>2017</year>) <volume>140</volume>:<fpage>2322</fpage>&#x2013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awx195</pub-id>
</citation>
</ref>
<ref id="B177">
<label>177.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lorenzo</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Slavutsky</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Spectrins: molecular organizers and targets of neurological disorders</article-title>. <source>Nat Rev Neurosci</source> (<year>2023</year>) <volume>24</volume>:<fpage>195</fpage>&#x2013;<lpage>212</lpage>. <pub-id pub-id-type="doi">10.1038/s41583-022-00674-6</pub-id>
</citation>
</ref>
<ref id="B178">
<label>178.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lynch</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Baudry</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Brain spectrin, calpain and long-term changes in synaptic efficacy</article-title>. <source>Brain Res Bull</source> (<year>1987</year>) <volume>18</volume>:<fpage>809</fpage>&#x2013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/0361-9230(87)90220-6</pub-id>
</citation>
</ref>
<ref id="B179">
<label>179.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>X-X</given-names>
</name>
<name>
<surname>Jeromin</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Spectrin breakdown products (SBDPs) as potential biomarkers for neurodegenerative diseases</article-title>. <source>Curr Translational Geriatr Exp Gerontol Rep</source> (<year>2012</year>) <volume>1</volume>:<fpage>85</fpage>&#x2013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1007/s13670-012-0009-2</pub-id>
</citation>
</ref>
<ref id="B180">
<label>180.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nilsson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Alafuzoff</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Blennow</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Blomgren</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Janson</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group> <article-title>Calpain and calpastatin in normal and Alzheimer-degenerated human brain tissue</article-title>. <source>Neurobiol Aging</source> (<year>1990</year>) <volume>11</volume>:<fpage>425</fpage>&#x2013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/0197-4580(90)90009-o</pub-id>
</citation>
</ref>
<ref id="B181">
<label>181.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peterson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vanderklish</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Seubert</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cotman</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Increased spectrin proteolysis in fibroblasts from aged and Alzheimer donors</article-title>. <source>Neurosci Lett</source> (<year>1991</year>) <volume>121</volume>:<fpage>239</fpage>&#x2013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1016/0304-3940(91)90694-o</pub-id>
</citation>
</ref>
<ref id="B182">
<label>182.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saito</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Elce</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Hamos</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Nixon</surname>
<given-names>RA</given-names>
</name>
</person-group>. <article-title>Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>1993</year>) <volume>90</volume>:<fpage>2628</fpage>&#x2013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.90.7.2628</pub-id>
</citation>
</ref>
<ref id="B183">
<label>183.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fiesco-Roa</surname>
<given-names>M&#xd3;</given-names>
</name>
<name>
<surname>Garc&#xed;a-de Teresa</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Leal-Anaya</surname>
<given-names>P</given-names>
</name>
<name>
<surname>van &#x27;t Hek</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wegman-Ostrosky</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fr&#xed;as</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Fanconi anemia and dyskeratosis congenita/telomere biology disorders: two inherited bone marrow failure syndromes with genomic instability</article-title>. <source>Front Oncol</source> (<year>2022</year>) <volume>12</volume>:<fpage>949435</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2022.949435</pub-id>
</citation>
</ref>
<ref id="B184">
<label>184.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stivaros</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Alston</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>NB</given-names>
</name>
<name>
<surname>Chandler</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bonney</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wynn</surname>
<given-names>RF</given-names>
</name>
<etal/>
</person-group> <article-title>Central nervous system abnormalities in Fanconi anaemia: patterns and frequency on magnetic resonance imaging</article-title>. <source>The Br J Radiol</source> (<year>2015</year>) <volume>88</volume>:<fpage>20150088</fpage>. <pub-id pub-id-type="doi">10.1259/bjr.20150088</pub-id>
</citation>
</ref>
<ref id="B185">
<label>185.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson-Tesch</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Gawande</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>MacMillan</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Nascene</surname>
<given-names>DR</given-names>
</name>
</person-group>. <article-title>Fanconi anemia: correlating central nervous system malformations and genetic complementation groups</article-title>. <source>Pediatr Radiol</source> (<year>2017</year>) <volume>47</volume>:<fpage>868</fpage>&#x2013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1007/s00247-017-3817-x</pub-id>
</citation>
</ref>
<ref id="B186">
<label>186.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aksu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Gumruk</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bayhan</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Co&#x15f;kun</surname>
<given-names>&#xc7;</given-names>
</name>
<name>
<surname>O&#x11f;uz</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Unal</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Central nervous system lesions in Fanconi anemia: experience from a research center for Fanconi anemia patients 184. Anemia patients</article-title>. <source>Pediatr Blood &#x26; Cancer</source> (<year>2020</year>) <volume>67</volume>:<fpage>e28722</fpage>. <pub-id pub-id-type="doi">10.1002/pbc.28722</pub-id>
</citation>
</ref>
<ref id="B187">
<label>187.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ackermann</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schrecker</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bon</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Friedrichs</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bankov</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wild</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group> <article-title>Downregulation of SPTAN1 is related to MLH1 deficiency and metastasis in colorectal cancer</article-title>. <source>PLoS ONE</source> (<year>2019</year>) <volume>14</volume>:<fpage>e0213411</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0213411</pub-id>
</citation>
</ref>
<ref id="B188">
<label>188.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hinrichsen</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ernst</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Nuber</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Passmann</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schafer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Steinke</surname>
<given-names>V</given-names>
</name>
<etal/>
</person-group> <article-title>Reduced migration of MLH1 deficient colon cancer cells depends on SPTAN1</article-title>. <source>Mol Cancer</source> (<year>2014</year>) <volume>13</volume>:<fpage>11</fpage>. <pub-id pub-id-type="doi">10.1186/1476-4598-13-11</pub-id>
</citation>
</ref>
<ref id="B189">
<label>189.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brieger</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Adryan</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wolpert</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Passmann</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zeuzem</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Trojan</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Cytoskeletal scaffolding proteins interact with Lynch-Syndrome associated mismatch repair protein MLH1</article-title>. <source>Proteomics</source> (<year>2010</year>) <volume>10</volume>:<fpage>3343</fpage>&#x2013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1002/pmic.200900672</pub-id>
</citation>
</ref>
<ref id="B190">
<label>190.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jain</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Spaeder</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Donofrio</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Sinha</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Jonas</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>RJ</given-names>
</name>
</person-group>. <article-title>Detection of alpha II-spectrin breakdown products in the serum of neonates with congenital heart disease</article-title>. <source>Pediatr Crit Care Med</source> (<year>2014</year>) <volume>15</volume>:<fpage>229</fpage>&#x2013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1097/pcc.0000000000000059</pub-id>
</citation>
</ref>
<ref id="B191">
<label>191.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lubbers</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>NP</given-names>
</name>
<name>
<surname>Musa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>CY-M</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>MV</given-names>
</name>
<etal/>
</person-group> <article-title>Defining new mechanistic roles for &#x3b1;II spectrin in cardiac function</article-title>. <source>J Biol Chem</source> (<year>2019</year>) <volume>294</volume>:<fpage>9576</fpage>&#x2013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.ra119.007714</pub-id>
</citation>
</ref>
<ref id="B192">
<label>192.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tulpule</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lensch</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Austin</surname>
<given-names>K</given-names>
</name>
<name>
<surname>D&#x2019;Andrea</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schlaeger</surname>
<given-names>TM</given-names>
</name>
<etal/>
</person-group> <article-title>Knockdown of Fanconi anemia genes in human embryonic stem cells reveals early developmental defects in the hematopoietic lineage</article-title>. <source>Blood</source> (<year>2010</year>) <volume>115</volume>:<fpage>3453</fpage>&#x2013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2009-10-246694</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>